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Figure 1.1 The tumor microenvironment (TME) heterogeneously consists of cellular and 
non-cellular components including the surrounding blood vessels, immune cells, 
fibroblasts, cancer stem cells and extracellular matrix (ECM).3 
Figure 1.2 Tumor-stromal interactions on a chip. (A) 3D Microfluidic model to investigate 
the carcinoma associated fibroblast promoted tumor spheroid invasion. (i, ii) microfluidic 
chip design (iii) cell loading step. Salivary gland adenoid cystic carcinoma cell line (ACC-
M) were co cultured with carcinoma associated fibroblasts (CAFs). ACC-M invaded CAF-
embedded matrix in a spheroid fashion. However, ACC-M cells did not invade the adjacent 
matrix when co-cultured with the fibroblast cell line (HFL1). (B) 3D culture of tumor 
spheroids and fibroblasts in a compartmentalized microfluidic chip. (i, ii) Fluorescence 
images of HT-29 tumor spheroids and CCD-18Co human normal fibroblast cell line. HT-
29 spheroids and CCD-18Co cells proliferated within the space of the corresponding 
channels over 5 days, during which their growth and interaction were monitored and 
characterized.4 
Figure 1.3 Tumor angiogenesis on a chip. (A) Human glioblastoma multiforme cells, 
(U87MG) were used to induce angiogenic sprouting. Fluorescence image shows 
angiogenic sprouts grown for 2 and 4 days under co-culture with U87MG cancer cells and 
human umbilical vein endothelial cells (HUVEC) (i, ii). Scale bar: 50 μm; (B) Pre-
vascularized tumor (PVT) spheroid model. PVT spheroid model were introduced breast 
cancer (MCF10A, MDA-MB-231), Lung cancer (A549) and colon cancer (SW620). 
Representative fluorescence images of PVT spheroid model shows robust angiogenic 
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sprouting. Various PVT spheroid showed different angiogneic sprouting behavior. 
Intravasation events were only observed for SW620 cancer cells. Scale bar: 100 μm.7 
Figure 1.4 Metastasis on a chip. (A) A human 3D vascularized organotypic microfluidic 
system to study cancer cell extravasation (i) Cancer cell extravasation was monitored in 
real time within a vascular network (ii) magnified image. Scale bar: 100 μm; (B) Human 
umbilical vein pericytes were cocultured with human umbilical vein endothelial cells to 
form pericyte-covered lumens. The extravasation rate from HUVEC-only cultures was 
significantly higher when compared to HUVEC-pericyte coculture. Scale bar: 20 μm; (C) 
Design of biomimetic multi-organ chip (i, ii) multi-organ chip included an upstream “lung 
organ” and three downstream “distant organ” such as bone, brain, liver; (iii, iv) The 
microfluidic chip was compartmentalized using human epithelial and stromal cells cultured 
on separated side of a porous membrane in order to mimic (v–vii) physiological respiration 
in the microfluidic system; which was followed by the introduction of (viii–x) lung 
fibroblast cells to investigate lung cancer metastasis to distant organ.8 
Figure 1.5 Probing the efficacy of drug delivery using TME on a chip. (A) Droplet-based 
microfluidic system for multicellular tumor spheroid formation and anticancer drug testing. 
(i) Schematic of the droplet formation and cell culture microfluidic chips. Each chamber 
contains 14 sieves for alginate droplet trapping; (ii) Breast tumor cells proliferating and 
forming multicellular spheroids while encapsulated in alginate beads. Tumor cells were 
perfused with doxorubicin and live/dead assay was assessed. Scale bar: 100 μm; (B) Tumor 
on a chip provides an optical window into nanoparticle tissue transport. (i) Schematic of 
the microfluidic device; (ii) MDA-MB-435 breast cancer cell embedded within 
microfluidic device (iii) Effect of nanoparticle size on tissue accumulation. 40 nm 
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fluorescent PEG-nanoparticles entered the tumor spheroid and accumulated in the 
interstitial spaces but 110 nm nanoparticles were excluded from the spheroid. Scale bar: 
100 μm.12 
Figure 2.1 In vitro three-dimensional vascularized tumor model. Schematic representation 
of microfluidic design for in vivo like 3D vascularized tumor formation by tumor spheroid 
and ECs mixture in the center channel under paracrine interactions with stromal fibroblasts 
in the outermost side channels.25 
Figure 2.2 Bright field images of the development of vascularized tumor spheroid, 
composed of tumor spheroid enveloped by endothelial cells. White and yellow lines 
indicate tumor spheroid area. Scale bars, 200 μm. 26 
Figure 2.3 (A) Representative confocal images compare before (left line)/after (right line) 
clearing in the same sample. CUBIC tissue clearing does not lead to volume changes. Scale 
bars, 150 μm. (A, below) 3D reconstruction image of vascularized tumor. Tumor spheroid 
is enveloped by blood vessels. (B) Before/after clearing comparison of z axis imaging 
depth. (C) Before/after clearing comparison of xy plane relative intensity according to 
distance. (D) Before tissue cleared confocal image of vascularized tumor spheroid (left, 
top). After tissue cleared vascularized tumor spheroid (left, bottom) and 3D reconstruction 
image of vascularized tumor spheroid (right).26 
Figure 2.4 Multicellular tumor spheroid characterization. (A) Representative confocal 
images of HepG2 – ECs spheroid with different cell ratio and spheroid sphericity of 
different cancer: EC ratios. All spheroid were fixed at day 5. (Scale bars, 100 μm. n=4-6). 
(B) RT-PCR results of cancer cell monoculture and cancer cell co-cultured with ECs. Gene 
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analysis considered markers 1) PTEN, 2) p53, 3) E-cadherin, 4) ɑ-SMA, 5) CXCL12 and 
CXCR4.The internal standard housekeeping gene was GAPDH. (n=3-4).28 
Figure 2.5 RT-PCR results of ECs monoculture and ECs co-cultured with tumor (HepG2) 
at day 2.29 
Figure 2.6 Representative confocal images compared total blood vessel volume induced by 
vascularized tumor model of cancer cell only (HepG2) spheroid and cancer cells HepG2 – 
ECs spheroid. (Scale bars, 400 μm. n=4-6).30 
Figure 2.7 Evaluation of vascularized tumor spheroid: permeability measurement and 
nanoparticle delivery. (A) Time series fluorescence micrographs were taken and analyzed 
for intensity changes in the perivascular region to measure permeability. After cell culture 
medium was removed, FITC-dextran (10kDa, 70kDa) solution was introduced and image 
were captured every 10 s. Red circles in bottom images represent focal intercellular 
openings (FIOs) (Scale bars, 100 μm) (B) The graphs shows permeability coefficient for 4 
different conditions (10 kDa) (n=5-6). (C) The graphs shows permeability coefficient for 
two conditions (70 kDa). (D) qRT-PCR result of ICAM-1 mRNA expression (n=3-4) (E) 
Number of focal intercellular openings. [ROI] 1; < 200 μm of the tumor spheroid boundary 
and [ROI] 2; > 200 μm of the tumor spheroid boundary (70 kDa).32 
Figure 2.8 Silica nanoparticle (NP) delivery through vasculature of vascularized tumor 
model at 3 time-points (top). Scale bars, 400 μm. Silica nanoparticle distribution at 
different z sections (bottom).34 
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Figure 2.9 Antiangiogenesis and antitumor activities of Axitinib in VTS model. (A) 
Timeline of cancer drug treatment experiment. In the early stage of vascularized tumor 
model, Axitinib were introduced into the reservoirs a day after spheroid – ECs gel 
suspension injected to the central channel. (B) Representative confocal images show 
Axitinib dosage dependent response of spheroid and vasculature in the early stage of VTS 
model. Scale bars, 300 μm. Relative spheroid area (C), blood vessel area (D), number of 
disconnected blood vessel (E) in response to two different dosage of Axitinib (1 nM, 10 
nM) at the early stage of VTS model. (F) Timeline of cancer drug treatment experiment. 
In the late stage of vascularized tumor model, Axitinib were introduced into the reservoirs 
4 days after spheroid – ECs gel suspension injected to the central channel, which 
vasculature fully enveloped HepG2 – ECs hybrid spheroid. (G) Representative confocal 
images show Axitinib dosage dependent response of spheroid and vasculature in the late 
stage of VTS model. Scale bars, 300 μm. Relative spheroid area (H), blood vessel area per 
device (I), number of disconnected blood vessel per device (J) in response to two different 
dosage of Axitinib (1 nM, 10 nM) at the late stage of VTS model.36 
Figure 2.10 Monitoring reliable and reproducible response of axitinib treatment. (A) 
Representative confocal images show 1 nM axitinib treated vascularized tumor spheroid 
conditions. (B) Spheroid area per device. Scale bar: 300 μm.36 
Figure 2.11 Confocal image of HepG2 – EC spheroid with lymphatic endothelial cells 
(LECs, green; podoplanin) and vascular endothelial cells (ECs, red). Scale bar: 150 μm.37 
Figure 3.1 Design of the standardized microfluidics platform for tumor spheroid-on-a-chip. 
(A) A conceptual image of Sphero-IMPACT based on a standard 96-well plate format. (B) 
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Sphero-IMPACT has a media reservoir on each side, centered on a fluid rail guide for cell 
culture. The rail guide contains a tapered hole functioned as a culture space for a cell 
spheroid. (C) Spontaneous fluid patterning by capillary action. Fluid can be transferred 
simply and robustly along the rail guide under hydrophilic condition. (D) The patterned 
fluid configures a concave meniscus at the edges of the structure. A fluorescence image 
showing GFP-expressing HUVECs patterned with fibrin gel which forming the meniscus, 
and RFP-expressing HUVECs seeded on the reservoir. (E) The cross-sections of the 
devices filled with a solution of Rodamin B under noted volume were converted to 
grayscale images for analysis. White dash lines indicate the fluid rail guide, and yellow 
dash lines are traces for curvature studies.53 
Figure 3.2 Overall schematics of the structural components of tumor spheroid-on-a-chip. 
(A)Illustration of 96-well plate SBS format-based microplate. (B) A single array of 
tumorspheroidon-a-chip as a prototype model. (C-D) Schematic view detailing the 
dimensions of the device. (E) Photograph of the dye being patterned into the rail of the 
device.54 
Figure 3.3 Process schematic of Sphero-IMPACT design optimization with 3D printing for 
mass production through injection molding. (A) 3D printing prototypes allow for rapid 
dimensional testing and optimization prior to high investment but high yield injection 
molded production. (B) During the process, we performed the platform validation through 
fluid patterning and cell culture testing. This process was approached through the trial and 
error method. (C) Once a design has been configured for injection molding, the design can 
be mass produced for easy accessibility for the end user.55 
 xv 
Figure 3.4 Fluid patterning under the hydrophilic and hydrophobic environment. 
(A)Investigation of the contact angle of the material used in the device under hydrophilic 
conditions to establish the fluid patterning technique. (B) The fluid interface showed 
surface imbalance under hydrophobic environment. After the plasma treatment, the fluid 
was well patterned under hydrophilic environment.58 
Figure 3.5 Various in vitro model approaches of Sphero-IMPACT. (A) Vasculogenesis; 
the platform can perform co-culture modeling to develop a 3D perfusable blood vessel 
networks. (B) Angiogenesis; induction of directional angiogenesis by attaching HUVECs 
to patterned fibrin gel-meniscus in a rail guide structure. (C) Tumor migration assay; ease 
of experimentation and observation through the space for a spheroid inside the platform. 
(D) Tumor spheroid-induced angiogenesis; construct tumor model which is vascularized 
through co-culture of tumor spheroid and blood vessel.59 
Figure 3.6 A diagram comparing the time required for production of the device between 
soft lithography and injection molding process.62 
Figure 3.7 Engineered 3D perfusable blood vessel networks in Sphero-IMPACT. (A) An 
illustration of angiogenesis model configuration in Sphero-IMPACT. (B) A cell culture 
approach to construct angiogenesis model. (C) Investigating an optimal patterned volume 
for inducing effective angiogenic sprouts. Every sample was cultured for 5 days and stained 
with lectins (green) as markers of endothelial cells. Scale bar = 1000 μm. (D) The total 
vascular network area and the number of vessel sprouts were quantitatively evaluated to 
determine appropriate conditions for angiogenesis depending on the patterning volume. (E) 
Experimental Study on the transport of microbeads with the lapse of time through 
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perfusable blood vessel developed under 6.0 μl patterning volume condition. Scale bar = 
500 μm. (F) Confocal images exhibiting vasculogenesis formed from GFP-expressing 
HUVECs reflecting the effect of LFs spheroids. Observation of cytoskeleton through F-
actin (red) antibody staining. Scale bar = 1000 μm.64 
Figure 3.8 Tumor invasion assay using a spheroid model. (A) Schematic depiction of tumor 
migration and invasion. (B) Configuration of the microfluidic device for modeling tumor 
spheroid migration and invasion into 3D ECM. (C) The optical microscope image showing 
the U87MG tumor spheroid in the spheroid region. Scale bar = 400 μm. (D) Representative 
confocal images of tumor migration and invasion under three different conditions. Scale 
bar = 600 μm. (E and F) Quantitative analysis of tumor cell migration area and migration 
distance. Bars indicate mean ± SEM from at least 4 devices per condition. *p < 0.1 and **p 
< 0.01 in the unpaired two-tailed Student's t-test.67 
Figure 3.9 Tumor spheroid-induced angiogenesis and drug screening validation (A) 
Schematic depiction of angiogenic sprouts toward tumor spheroid positioned in the center 
hole. (B) Configuration of the microfluidic platform for modeling tumor angiogenesis. The 
tumor spheroid collected and mixed with fibrin gel is injected into the hole, and HUVECs 
are seeded on around the fibrin gel surface. (C) Maximum projection images of the tumor 
angiogenesis cultured for 4 days in Sphero-IMPACT. Tumor spheroid formed from GFP-
expressing U87MG, and blood vessels assembled from RFP-expressing HUVECs. Under 
the same culture conditions, the types of target drugs were treated with medium every two 
days. Scale bar = 500 μm. (D–F) Quantitative analysis of the total vascular network area, 
number of sprouts and sprouting length depending on each drug condition. Bars represent 
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mean ± SEM from at least 8 devices per condition. ****p < 0.0001 in the unpaired two-
tailed Student's t-test.71 
Figure 3.10 Comparison of angiogenic sprouts under different conditions. Under co-culture 
with U87MG cancer cells, angiogenic sprouts are characterized by the sprouts with 
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The “Tumor microenvironment” (TME) has been increasingly recognized as an underlying 
factor in drug resistance and the recurrence of cancer, both of which are major obstacles to 
a cure. The TME is a complex, interacting system including the tumor itself, other 
noncancerous cell types such as immune, stromal and endothelial cells, and the 
extracellular matrix surrounding these cells. This complexity has largely prevented a 
comprehensive understanding of TME in conventional in vitro models, which have been 
too simple to recapitulate the intricate interactions. Therefore, developing in vitro assays 
that closely replicate the pathophysiology of 3D vascularized TME is critical to understand 
the formation and development of tumors and unravel the mechanisms by which tumor 
cells grow, metastasize, and resist against drugs.  
To this end, this thesis first describes the method to create in vivo like vascularize tumor 
spheroid Polydimethylsiloxane (PDMS)-based model. We developed vascularized tumor 
spheroid (VTS) model that reproduces the pathological and morphological characteristics 
of in vivo vascularized solid TME. We used human hepatocellular carcinoma (HepG2) 
spheroid to reconstitute VTS. The VTS structure closely recapitulates a vascularized tumor 
microenvironment where cancer cells can interface with self-assembled vascular 
endothelial cells within 3D hydrogel. We introduced on-chip tissue clearing technology 
that enables 3D intact visualization of the tumor-endothelium interaction. We also 
conducted comparative studies of spheroid morphology, relative tumor suppressor (PTEN 
and p53) and epithelial-mesenchymal transition (EMT) gene expressions, and 
microvascular network formation induced by the spheroid. Notably, we observed that 
 xxi 
cancer-EC hybrid spheroids enhance uniformity of spheroid, tumor aggressiveness, and 
tumor angiogenesis compared to those with cancer cells only. Moreover, the 
microvasculature co-cultured with the tumor spheroid showed a higher permeability 
coefficient compared to control and increased focal intercellular openings (FIOs) of 
microvascular network located in adjacent to tumor spheroid, demonstrating hallmarks of 
tumor vasculature; a leaky and fenestrated structure of endothelium. We further visualized 
and quantitatively demonstrated the effects of the FDA approved cancer drug; Axitinib by 
monitoring blood vessel area and spheroid tumor size, highlighting the significance of 
tumor vascularization and revealing the importance of the dose and treatment timing. The 
3D VTS model will be a useful platform to better understand how tumor develops and 
metastasizes in vasculature, screen drugs and their compositions (fine drug cocktails) for 
heterogeneous cancer treatment, and explore new therapeutic strategies with 3D 
vascularized models of patient-derived multicellular tumor spheroids. 
Secondly, this thesis introduces Injection-molded based vascularized tumor 
microenvironment platform considering standardized application for industrialization. The 
field of microfluidics-based three-dimensional (3D) cell culture system is rapidly 
progressing from academic proof-of-concept studies to valid solutions to real-world 
problems. PDMS-based platform has been widely adopted as in vitro platforms for 
mimicking tumor microenvironment. However, PDMS has not been welcomed as a 
standardized commercial application for preclinical screening due to inherent material 
limitations that make it difficult to scale-up production. Here, we present an injection-
molded plastic array 3D spheroid culture platform (Sphero-IMPACT). The platform is 
made of polystyrene (PS) in a standardized 96-well plate format with a user-friendly 
 xxii 
interface. This interface describes a simpler design that incorporates a tapered hole in the 
center of the rail to pattern a large spheroid with 3D extracellular matrix and various cell 
types. This hole is designed to accommodate standard pipette tip for automated system. 
The platform that mediate open microfluidics allows implement spontaneous fluid 
patterning with high repeatability from the end user. To demonstrate versatile use of the 
platform, we developed 3D perfusable blood vessel network and tumor spheroid assays. In 
addition, we established a tumor spheroid induced angiogenesis model that can be 
applicable for drug screening. Sphero-IMPACT has the potential to provide a robust and 
reproducible in vitro assay related to vascularized cancer research. This easy-to-use, ready-
to-use platform can be translated into an enhanced preclinical model that faithfully reflects 





CHAPTER 1. INTRODUCTION 
The cost of drug development has dramatically increased during the last several 
decades due to the inefficiency of current pre-clinical drug screening models. Major 
disadvantages of conventional drug screening models are (i) the dissimilarity between two-
dimensional (2D) in vitro cell culture systems and in vivo models; and (ii) the phylogenetic 
difference between human and animal models. Advanced 3D cell culture model systems 
have demonstrated advantages in providing more physiologically relevant conditions and 
more predictive ability [1, 2]. The integration of microfluidic technology and cell biology 
research has recently reached a significant milestone with the development of “organ-on-
a-chip” technologies that reconstitute organ-level in vivo characteristics [3]. Developing 
improved in vitro models through these innovative technologies will promote fundamental 
cancer research and accelerate drug discovery and clinical translation.  
A tumor microenvironment (TME) consists of a heterogeneous mix of cellular and 
non-cellular components including surrounding blood vessels, immune cells, fibroblasts, 
cancer stem cells and extracellular matrix (ECM) (Figure 1) [4]. The elucidation of the 
complex cellular interactions within the TME remains one of the main challenges in the 
treatment of cancer [5]. It has become increasingly recognized that the study of human 
cancer cannot be simplified to homogeneous collections of neoplastic cells, but must 
instead be studied as complex multicellular systems to properly reflect interactions between 
malignant and non-malignant cells [1, 6, 7]. This interplay between the tumor and the 
stroma has been recognized as a characteristic property of the TME, and this paradigm is 
now considered to be a hallmark of cancer biology [8]. Animal models are conventionally 
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the gold standard for screening cancer therapeutics because of their capabilities to sustain 
the complex TME [9]. However, accurate mimicry of human tumorigenesis is extremely 
difficult, questioning the usefulness of existing in vivo models for therapeutic efficacy 
translation. Meanwhile, recent advancements in the microengineering of TME using organ-
on-a-chip technologies have enabled the development of pathophysiologically relevant 
human tumorigenesis models. 
In this thesis, we proposed a novel, physiologically relevant in vitro vascularized 
tumor microenvironment models. Using the advanced 3D microengineered technology, we 
developed two microfluidic platforms: PDMS and injection-molded microfluidic platforms.  
We designed geometrically defined vascularized tumor spheroid model and investigated 
hallmarks of tumor vasculatures using PDMS platform. We also highlighted significance 
of tumor vascularization and revealing the importance of treatment timing. Based on the 
model, we further developed injection-molded plastic array 3D spheroid culture platform, 
which made of polystyrene (PS) in a standardized 96-well plate format with user-friendly 
interface. We propose vascularized tumor spheroid model as the next generation of 3D 
microfluidic system for robust high-throughput and high-content assays with drug 




Figure 1.1 The tumor microenvironment (TME) heterogeneously consists of cellular and 
non-cellular components including the surrounding blood vessels, immune cells, 
fibroblasts, cancer stem cells and extracellular matrix (ECM). 
1.1 Tumor-Stromal Interactions on a Chip 
Tumors interact with the surrounding microenvironments incessantly. Tumors typically 
consist of cancer cells and stromal cells (i.e., fibroblast and immune cells) that are 
nourished through vascular networking. Understanding the interactions between the tumor, 
stroma, and vasculature is key to the development of cancer treatments. Especially, the 
stromal cells and tumor microenvironment modulate tumor sensitivity, which affects tumor 
cell signaling, proliferation, and drug resistance [10]. Emerging microfabrication 
techniques enable the reconstitution of complex in vitro co-culture models for studying 
tumor-stromal interactions. Microfluidic systems provide greater spatial organization 
through controlled compartmentalization and higher sensitivity and control over the 
diffusion of soluble factors than traditional Transwell inserts [11]. Several key microfluidic 
tumor-stromal co-culture models have been developed to investigate the interactions. A 
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microfluidic device designed to study salivary gland adenoid cystic carcinoma (ACC) cells 
and CAFs interactions when seeded in a 3D ECM has shown the potential of these 
platforms as a high-throughput parallel co-culture assay. This approach revealed that CAFs 
promoted ACC cell invasion into the 3D matrix, identifying a potential target for anti-
cancer chemotherapies (Figure 1.2A) [12]. In addition to compartmentalized microfluidics, 
several other approaches have been developed to study cancer-stromal interactions. 
Continuous media supplementation allowed for 3D culture of a mixture of lung cancer cells 
and stromal cells for studies of the cancer-stromal cellular interactions [13]. Recently, 
microfluidic systems offered a physiologically relevant in vitro tumor spheroid model to 
study the TME. Integrating 3D tumor spheroids with CAFs in proximity within a hydrogel 
scaffold exhibited mutual interactions (e.g., growth rate, ECM expression, morphological 
changes and increased migration in fibroblast) between the spheroids and fibroblasts 
(Figure 1.2B) [14].  
 
Figure 1.2 Tumor-stromal interactions on a chip. (A) 3D Microfluidic model to 
investigate the carcinoma associated fibroblast promoted tumor spheroid invasion. (i, ii) 
microfluidic chip design (iii) cell loading step. Salivary gland adenoid cystic carcinoma 
cell line (ACC-M) were co cultured with carcinoma associated fibroblasts (CAFs). ACC-
M invaded CAF-embedded matrix in a spheroid fashion. However, ACC-M cells did not 
invade the adjacent matrix when co-cultured with the fibroblast cell line (HFL1). (B) 3D 
culture of tumor spheroids and fibroblasts in a compartmentalized microfluidic chip. (i, 
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ii) Fluorescence images of HT-29 tumor spheroids and CCD-18Co human normal 
fibroblast cell line. HT-29 spheroids and CCD-18Co cells proliferated within the space of 
the corresponding channels over 5 days, during which their growth and interaction were 
monitored and characterized. 
In addition to fibroblasts, cancer cells actively recruit macrophages to remodel the TME 
and produce growth factors that increase the invasiveness of cancer cells [15]. MDA-MB-
231 metastatic breast cancer cells and tumor-associated macrophages were embedded in 
collagen I and patterned within a microfluidic channel. It was found in this study that the 
tumor-associated macrophages invade the neighboring gels containing MDA-MB-231 
cells, rather than migrating [16].  
 As Stephen Paget suggested in the “Seed & Soil” hypothesis in 1889, tumor cells 
are like seeds being carried in all directions only if they settle into an appropriate soil. 
Stromal cells and ECM (soil) play a mutual supportive role in the initiation and progression 
of carcinogenesis (seeds). It remains extremely difficult to fully replicate the complex 
tumor-stromal interactions, although many microfluidic systems have created successful 
TMEs to study tumor-stromal interactions within microfluidic chips. Therefore, the critical 
elements to be mimicked or possibly ignored in a specific TME model should be carefully 
defined in a study to clarify the domain over which the study is relevant.  
1.2 Tumor-Vasculature Interactions on a Chip 
Tumor growth and metastasis depend on angiogenic vascular networks, the growth of 
which are largely guided by chemical signals from tumor cells. Without the formation of 
new blood vessels, carcinomas neither grow well nor metastasize to colonial distant organs 
[17]. This rapidly growing angiogenic vasculature around the tumor is highly leaky, 
forming an aberrant vascular architecture [18]. Several 3D microfluidic systems have been 
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developed to mimic these characteristics of cancer angiogenesis. Many of these 
microsystems allowed 2D endothelial monolayers to be vertically established in the side 
walls, which is designed to better image angiogenic sprouting into a 3D hydrogel. For 
example, a fibrin gel was either patterned into a microfluidic channel as a provisional 
matrix for endothelial sprouts or into a side channel for highly malignant human 
glioblastoma (U87MG). Endothelial cells (ECs) that were attached to the fibrin gel formed 
a pre-existing wall, 3D sprouting was promoted by the U87MG secretion factors. When 
compared to lung fibroblast-induced sprouts, U87MG-induced sprouts exhibited aberrant 
morphology, which is a general characteristic of cancer vasculature (Figure 1.3A) [19]. In 
addition, leukemic-cell-induced bone marrow angiogenesis has been demonstrated using a 
microfluidic chip, in which a collagen gel was filled into the middle channel, and U937, 
HL-60 and K562 cell lines were seeded into an upper channel to study their angiogenic 
induction. Upon forming the microenvironment of a bone marrow stromal cell line HS5, a 
unique morphogenic signature of angiogenesis was induced by different types of leukemic 
cells with or without co-culture with bone marrow stromal cells [20]. In order to study the 
complex multicellular interactions in a completely three-dimensional setting, a pre-
vascularized tumor (PVT) spheroid model was introduced to investigate early events of 
solid tumor progression. PVT spheroids were formed through direct co-culture of EC and 
tumor cells and embedded in a fibrin gel mixed with human fibroblasts. After 7 days of 
culture, PVT spheroids exhibited robust sprouting angiogenesis (Figure 1.3B) [21]. Despite 
major advances in the development of tumor-angiogenesis-on-a-chip devices, the 
mechanisms by which tumor cells interact with the TME remain to be further studied. 
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Figure 1.3 Tumor angiogenesis on a chip. (A) Human glioblastoma multiforme cells, 
(U87MG) were used to induce angiogenic sprouting. Fluorescence image shows 
angiogenic sprouts grown for 2 and 4 days under co-culture with U87MG cancer cells 
and human umbilical vein endothelial cells (HUVEC) (i, ii). Scale bar: 50 μm; (B) Pre-
vascularized tumor (PVT) spheroid model. PVT spheroid model were introduced breast 
cancer (MCF10A, MDA-MB-231), Lung cancer (A549) and colon cancer (SW620). 
Representative fluorescence images of PVT spheroid model shows robust angiogenic 
sprouting. Various PVT spheroid showed different angiogneic sprouting behavior. 
Intravasation events were only observed for SW620 cancer cells. Scale bar: 100 μm. 
1.3 Cancer Cells Transmigration through Vasculature: Metastasis on a Chip 
In metastasis, cancer cells spread locally or distally by traveling through the blood or the 
lymphatic system to form a new tumor in other regions of the body [22]. This metastatic 
process involves a broad spectrum of invasion and migration mechanisms that include both 
single and collective cell migration strategies [23]. During metastasis, cancer cells 
disseminate to other parts of the body by entering the blood stream (intravasation) and 
getting out of the blood (extravasation) at proper metastatic sites [24]. Several microfluidic 
systems have been developed to mimic cancer cell transmigration through an endothelial 
cell lining. A 3D tumor vasculature interface was recreated in a microfluidic assay to 
characterize their interactions through tumor cell migration efficacy and endothelial 
permeability [25]. A microfluidic system was developed to mimic the specificity of human 
breast cancer metastasis into bone tissue by recreating a vascularized osteo-cell conditioned 
 8 
microenvironment with BM-hMSC that secreted a bone-like matrix [26]. This was further 
developed to study human metastatic breast cancer cell extravasation within a perfusable 
human microvascularized bone-mimicking microenvironment (Figure 1.4A) [27]. The 
method of implementing an in vitro model of metastasis in human microcirculation was 
given through multiple steps: early metastatic seeding, arresting, and transendothelial 
migration (Figure 1.4B) [28]. Recently, a multi-organ microfluidic platform was developed 
to reconstitute an in vivo microenvironment of lung cancer metastasis. This study 
successfully reproduced lung cancer growth, invasion, and metastasis to target distant 
organs including bone, brain and liver (Figure 1.4C) [29]. 
 
Figure 1.4 Metastasis on a chip. (A) A human 3D vascularized organotypic microfluidic 
system to study cancer cell extravasation (i) Cancer cell extravasation was monitored in 
real time within a vascular network (ii) magnified image. Scale bar: 100 μm; (B) Human 
umbilical vein pericytes were cocultured with human umbilical vein endothelial cells to 
form pericyte-covered lumens. The extravasation rate from HUVEC-only cultures was 
significantly higher when compared to HUVEC-pericyte coculture. Scale bar: 20 μm; (C) 
Design of biomimetic multi-organ chip (i, ii) multi-organ chip included an upstream 
“lung organ” and three downstream “distant organ” such as bone, brain, liver; (iii, iv) The 
microfluidic chip was compartmentalized using human epithelial and stromal cells 
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cultured on separated side of a porous membrane in order to mimic (v–vii) physiological 
respiration in the microfluidic system; which was followed by the introduction of (viii–x) 
lung fibroblast cells to investigate lung cancer metastasis to distant organ. 
1.4 Tumor-Extracellular Matrix Interaction  
The extracellular matrix (ECM), the key non-cellular component of the TME, consists of 
several distinct components including proteins and glycoproteins [30]. Tumor growth is 
associated with mechanical alteration in the microenvironment, including increased matrix 
stiffness and aberrant interstitial fluid flow [31]. Various microfluidic models have 
incorporated 3D ECM matrix components and hydrogels into compartmentalized channels 
[32]. Fibrin gels [19], collagen gels [33], and matrigels have been commonly used to 
reconstitute 3D microenvironments. These gels have the capacity to not only support tumor 
stroma such as fibroblasts and immune cells, but also to modify diffusion distance that 
allows for greater spatial control between different cell types. Furthermore, cancer cells in 
their intrinsic environment interact with a 3D ECM, characterized by physical parameters 
(e.g., porosity and stiffness) and by chemical parameters (e.g., adhesion site density and 
bound ligand concentration) [34]. Increased physical parameters of ECM alter the cellular 
force balance, leading to abnormal cell proliferation [35], , and especially, increase in the 
rigidity of the matrix activates integrins and promotes Rho/ROCK pathway [36]. The 
crosstalk between the integrin/Rho pathway and Erk signaling cascade may induce self-
sustaining process, leading to neoplastic disorganization of cancer tissue architecture [34]. 
In addition, it is crucial to note that our understanding of cell migration in 3D ECM is based 
largely on fibrous matrices, such as collagenous matrix found in the breast and other 
connective tissues [37]. However, other tissues are composed of non-collagenous, less 
structured materials [38]. For example, brain ECM is composed of hyaluronic acid and 
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proteoglycans which form a more amorphous matrix [39]. Therefore, it is important to 
understand how their unique architecture contributes to tumor growth, and that the 
systematic consideration of 3D ECM properties should serve as an informative set of 
design criteria in the TME on a chip. 
1.5 Microfluidic Platforms for Cancer Drug Delivery and Screening 
3D microfluidic culture models are increasingly being used as prescreening tools for drug 
discovery including drug delivery and translation in oncology [40]. These models present 
more pathophysiologically relevant microenvironments of solid tumors in which the direct 
cell-cell interactions and metabolic mechanisms are better recapitulated in 3D multicellular 
spheroids than in conventional 2D cell culture models. Conventional routes to screening 
compounds are a time-consuming and complex procedure [41]. Microfluidic systems have 
the potential to enable high-throughput drug screening in a controllable and scalable 
manner [42]. A droplet-based microfluidic system was used to form alginate beads with 
entrapped breast tumor cells. After gelation, the alginate beads were trapped in a 
microsieve structure for cell culture in a continuous perfusion system. This microfluidic 
system maintained a constant location for each bead to allow tumor cells to proliferate and 
form spheroids. The dose-dependent response of the tumor spheroids to doxorubicin, a 
common anthracycline, showed a higher survival rate in the multicellular spheroid culture 
compared to the conventional monolayer culture (Figure 1.5A) [43]. Tumor spheroids have 
several structural, functional, and physiological similarities to tumors in vivo. 3D tumor 
spheroids enable them to communicate with each other as well as with their surroundings 
and provide an optimal environment for the cells to respond like they would in a tumor 
[44]. Furthermore, the inclusion of stromal cells to tumor cell culture showed a 
 11 
significantly higher drug resistance compared to when tumor cells were cultured alone [13]. 
Furthermore, pH and oxygen sensor integrated microfluidic systems allowed the 
monitoring of the long-term response of T98G human brain cancer cells to several drugs 
[45]. Recent studies consider the importance of the TME properties when evaluating 
nanoparticles targeting tumor cells. A tumor-microenvironment on a chip (T-MOC) was 
used to investigate nanoparticle transport and the resulting variation to delivery efficacy 
due to changes in the TME properties including cut-off pore size, interstitial fluidic 
pressure, and tumor tissue microstructure [46]. To recapitulate the complex transport 
process around a tumor, the T-MOC employed a 3D structure formed by stacking 
microchannels with a porous membrane inserted. The capillary endothelium was cultured 
on the top layer, and the tumor interstitium and lymphatics were created in the bottom layer. 
Furthermore, incorporation of tumor-like spheroids into a microfluidic channel allowed for 
the real-time analysis of nanoparticle accumulation in pathophysiological flow conditions, 
showing that the penetration of nanoparticles into the tissue is limited by their diameter 
and that the retention could be improved by receptor targeting (Figure 1.5B) [47]. To gain 
a better understanding of cancer drug screening, more physiologically relevant models 
need to be developed to reconstitute the complex interactions within the TME that is known 
to increase drug resistance. The majority of the microfluidic systems employed in drug 
delivery rely on diffusive drug release over an extended time period, as the drug 
administration period lasts from several hours to weeks. To better mimic a physiological 
drug release profile, various flow patterns need to be incorporated with multiple cell types 
that exist in the TME, as pulsatile flow patterns are prevalent in vivo. 
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Figure 1.5 Probing the efficacy of drug delivery using TME on a chip. (A) Droplet-based 
microfluidic system for multicellular tumor spheroid formation and anticancer drug 
testing. (i) Schematic of the droplet formation and cell culture microfluidic chips. Each 
chamber contains 14 sieves for alginate droplet trapping; (ii) Breast tumor cells 
proliferating and forming multicellular spheroids while encapsulated in alginate beads. 
Tumor cells were perfused with doxorubicin and live/dead assay was assessed. Scale bar: 
100 μm; (B) Tumor on a chip provides an optical window into nanoparticle tissue 
transport. (i) Schematic of the microfluidic device; (ii) MDA-MB-435 breast cancer cell 
embedded within microfluidic device (iii) Effect of nanoparticle size on tissue 
accumulation. 40 nm fluorescent PEG-nanoparticles entered the tumor spheroid and 
accumulated in the interstitial spaces but 110 nm nanoparticles were excluded from the 
spheroid. Scale bar: 100 μm. 
 
1.6 PDMS and Injection-molded Microfluidic System 
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Conventional microfluidic platforms have historically utilized soft lithographic fabrication 
methods with replica-molded polydimethylsiloxane (PDMS) [48]. The advent of PDMS 
microfluidic systems allowed for unprecedented control over cell patterning and 
microphysiological conditions with a reduction in the cell and media requirements. Recent 
advances in microfluidic vascularized tumor co-culturing have exploited soft lithography 
to fabricate microchannels and compartments to simulate the incorporation of cancerous 
masses into established vessel networks, the formation of new vessel networks in tumor 
tissues, and the observation of metastatic intra/extravasation [49]. Unfortunately, soft 
lithographic fabrication methods have several material and logistical limitations related to 
their scalability and the accessibility of microfluidic platforms for industrial-scale 
integration [50]. Although soft lithographic replica molding is one of the most commonly 
used techniques for pilot-scale production, the expensive and rate-limited fabrication 
processes that are used render soft lithography unsuitable for industrial-scale mass 
production [51]. In addition, the lack of an industry standard form factor and the 
incorporation of many hand-processed fabrication practices introduce challenges for 
advancing to automated loading, handling, and imaging procedures. Limited attempts at 
standardizing PDMS microfluidic inputs have not yet seen wide scale implementation. 
Small molecule adsorption into PDMS also poses a problem for the establishment of 
controlled dosages for drug development applications. The application of microfluidic 
organ-on-chip designs to injection molded thermopolymer substrates such as polystyrene 
(PS) has been a large trend in microfluidics as a means for the production of highly scalable 
devices that do not exhibit the same adsorptive material limitations of PDMS [51, 52]. 
Mass-producible injection-molded microfluidic platforms provide a higher degree of 
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uniformity between devices due to the minimization of human-manipulated production 
steps that are prevalent in pilot-scale PDMS replica molding. Such methods also allow for 
the implementation of higher-throughput experimentation and require less time and effort, 
which could potentially improve the efficiency of drug development. 
1.7 Aims and Approaches  
This study focused upon five predominant aims in order to address unmet needs in 
mimicking vascularized tumor microenvironment. The major aims of this study were:  
1. To establish an in vitro model of direct interaction between the tumor spheroid and 
vascular endothelial cells in 3-dimensional and find optimal condition for tumor 
spheroid formation, tumor spheroid vascularization and tumor vasculature 
perfusion with natural endothelial morphogenesis in making the lumenized 
structure. 
2. To investigate the characteristic features and response of in vivo TME vasculature; 
leaky and aberrant tumor vasculature. 
3. To evaluate the developed vascularized tumor model for demonstrating a proof-of-
concept application of the model for drug screening with varied dose and treatment 
timing by monitoring tumor spheroid and vasculature simultaneously. 
4. To establish an injection-molded plastic array 3D spheroid culture platform, which 
made of polystyrene (PS) in a standardized 96-well plate format with a user-
friendly interface. 
5. To demonstrate versatile use of the injection-molded plastic array 3D spheroid 
culture platform, we developed 3D perfusable blood vessel network and tumor 
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spheroid assays. In addition, we established a tumor spheroid induced angiogenesis 
model that can be applicable for drug screening. 
 
Although many in vitro tumor-on-a-chip model have been developed, the three-
dimensional vascularized tumor spheroid model that closely recapitulate in vivo 
tumor microenvironment is still absent. Therefore, we presented a 
micropathological system of a 3D in vitro perfusable vascularized tumor model 
that recapitulates the close interactions of tumor spheroids, endothelial cells, and 
stromal fibroblasts.  Also, for tumor-on-a-chip industrial application, by utilizing a 
standardized injection-molded PS platform and capillary force-based fluid 
patterning, we introduced a novel injection-molded plastic array 3D spheroid 
culture (IMPACT) platform, which may serve as a mass-producible platform for 
wider applications. We propose our platforms as the next generation of tumor-on-
a-chip for biological, clinical, and pharmaceutical investigations requiring robust 






CHAPTER 2. PDMS 3D CULTURE PLATFORM: 
VASCULARIZED TUMOR SPHEROID CULTURE  
2.1 3D Microengineered Vascularized Tumor Spheroid Model for Drug Delivery 
and Efficacy Testing  
The tumor microenvironment (TME) plays an active role in tumor initiation and 
development. Tumor cells efficiently recruit endothelial cells (ECs) and other stromal cells 
(e.g., fibroblasts) through intricate pathways, in turn providing tumor cell growth signals, 
intermediate metabolites, and favorable environments for tumor progression and metastasis 
[53]. Tumor growth depends on angiogenesis that occurs with growth factors (e.g., VEGF) 
secreted by tumor cells [7]. Tumor angiogenesis is one valid therapeutic target of many 
solid tumors, and particularly of their metastasis [54]. The TME is comprised of cellular 
and non-cellular components, including surrounding blood vessels, fibroblasts, immune 
cells, cancer stem cells, and extracellular matrix (ECM) [55]. The elucidation of these 
complex cellular interactions within the TME remains a key challenge in the treatment of 
cancer. It is increasingly recognized that cancer should be studied as complex multicellular 
systems to properly reflect the interactions between malignant and non-malignant cells, not 
as simplified as conventional models leveraging homogenous collections of neoplastic 
cells [56]. This interplay between the tumor and stroma has been recognized as a critical 
characteristic of the TME, and this paradigm is now in turn considered to be a hallmark of 
cancer research [57]. 
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Nevertheless, most in vitro studies exploit two-dimensional (2D) tumor cell cultures with 
no consideration of the TME, which is not suitable to study the effects of the complex 
spatial organization and interaction of tumor-associated cells [58]. While xenograft animal 
models of cancer can provide essential in vivo characteristics on tumor growth and 
responses to drug molecules, it remains extremely difficult to accurately mimic the process 
of human tumorigenesis due to species discrepancies and limited mechanistic approaches 
of animal models [9]. This challenge highlights the importance of more realistic TME 
modeling in vitro. Recent advances in engineered TME using multicellular organ-on-a-
chip technology have enabled the development of pathologically and physiologically 
relevant human tumorigenesis models of processes, such as tumor metastasis [27, 59], 
tumor angiogenesis [60, 61], and tumor-stroma interactions [14, 62]. 
The multicellular tumor spheroid model is the most advanced, widely used method to 
mimic the solid TME [63, 64]. Tumor spheroids are compact heterogeneous cellular 
aggregates that consist of multiple single cells (e.g., epithelial, mesenchymal, endothelial). 
Distinct from those of 2D cultures and biopsy samples, multicellular spheroids can provide 
proliferative gradients, reduced drug and gas exchange, and cell–cell and cell–ECM 
interactions [65]. Therefore, tumor spheroid models are considered the gold standard for 
avascular in vitro tumor research [66]. To better understand the interaction between cancer 
cell and endothelial cells within the spheroid, cancer cells – endothelial cell multicellular 
spheroids have been investigated of their morphology and spatial invasiveness [67]. Indeed, 
several microfluidic approaches have made important progress toward the recapitulating 
in vivo TME [68, 69]. Nonetheless, these microfluidic approaches failed to provide 
sufficiently large enough (as large as 500 μm) tumor spheroid for mimicking a necrotic 
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core and gradient distributions of critical metabolites and growth factors that can be 
obtained from solid tumor mass [70]. Multicellular (cancer cells – fibroblasts) spheroid 
connected with vessel-like tubular structure model evaluated the drug response of 
paclitaxel and gemcitabine [71]. Unfortunately, as this vascularized TME models did not 
follow natural endothelial morphogenesis in making the lumenized structure, they were 
still limited in their ability to reconstitute the characteristic features and response of in vivo 
TME endothelium; leaky and aberrant tumor vasculature. In addition, there is no in vitro 
TME models have been reported the direct interactions between tumor spheroids (> 500 
μm in diameter) and ECs within a 3D ECM, integrating with 3D perfusable blood vessel 
network.  
Here we present a micropathological system in a 3D in vitro perfusable vascularized tumor 
model that recapitulates the close interactions of tumor spheroids, ECs, and stromal 
fibroblasts. We incorporated multicellular tumor spheroids (> 500 μm in diameter) into a 
microfluidic chip that allows the co-culture of 3D perfusable microvessels exhibiting 
paracrine interactions with stromal fibroblasts. Subsequently, the tumor spheroid was 
enveloped by perivascular ECs, which was validated using CUBIC tissue-clearing method 
that reduces light scattering in biological tissues by lipid removal and refractive index (RI) 
matching. By this method, we were able to visualize 3D tumor spheroid–vasculature 
structures. We first cultured and compared cancer cell only and cancer–EC hybrid 
spheroids, and analyzed their morphological characteristics and relative gene expression. 
Notably, we found that the cancer–EC hybrid spheroids showed greater pro-angiogenic 
behavior than the cancer cell only spheroid. We next investigated permeability coefficient 
of the tumor spheroid associated vasculature and monitored tumor spheroid size and 
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vasculature area in response to the FDA approved cancer drug; Axitinib using the 
vascularized tumor model with highlighting the importance of tumor vascularization and 
revealing the significance of the dose and treatment timing. Such 3D vascularized tumor 
model could closely recapitulate morphological characteristic of in vivo solid tumor, 
representing a promising platform for in vitro pre-clinical experimentation. 
2.2 Materials and Methods 
2.2.1 Cell culture 
Human umbilical vein endothelial cells (HUVECs, Lonza) were cultured in Endothelial 
Growth Medium (EGM-2) and passage 4 was used for the experiments. Red fluorescent 
protein (RFP) expressing HUVECs were obtained from Anigio-Proteomie (Boston, MA). 
Normal human lung fibroblasts (LFs, Lonza) were cultured in Fibroblast Growth Medium 
(FGM-2, Lonza) and passage 6 was used for the experiments. Human hepatocyte 
carcinoma cells (HepG2, Korean Cell Line Bank) were cultured in DMEM supplemented 
with 10 % FBS, penicillin (100 U/ml) and streptomycin (100 U/ml). All cells were 
maintained in a humidified incubator at 37 °C and 5% CO2. In this study, we prepared four 
kinds of spheroids: a HepG2 monoculture spheroid HepG2 and HUVEC co-culture 
spheroid with different ratio (1:4, 1:1, and 4:1) They were grown in a 96-well plate with 
U-shaped bottom wells (Sumitomo Bakelite, Tokyo, Japan). For suspension culture, EGM-
2 medium was used for the cancer monoculture spheroid and the co-culture spheroid. All 
cell suspensions were prepared for total 5000 cells and mixed with 1% volume ratio of 
Matrigel in 200 μL of medium. After pre-culturing in a 96-well plate, a spheroid was 
introduced into the VTS device. We used 4 to 6 days cultured spheroid for the experiments. 
 20 
2.2.2 Cell seeding in the microfluidic platform 
A tumor spheroid was collected from a 96-well plate using a 200 μL pipette tip and mixed 
with HUVECs suspension in the fibrinogen solution, at a concentration of 5 × 106 cell/mL. 
The cell and spheroid solution were mixed with thrombin (0.5 U/ml, Sigma) and then 
immediately introduced into a central channel and settled at the bottom of the channel 
(Figure 2.1). Because the diameter of the spheroid (> 500 μm) was greater than the channel 
height (150 μm), the spheroid was set to be stationary at the bottom of the channel. When 
the spheroid-ECs gel suspension was injected, an excess amount of the HUVEC and gel 
flowed out through the other two outlet of center channel and did not leak to media channel. 
The spheroid-ECs suspended gel was allowed to clot for 5 min at room temperature. Next, 
LFs were suspended in the fibrinogen solution, mixed with thrombin (0.5 U/mL, Sigma) 
and then immediately injected into left and right stromal cell culture channel. The inlet 
reservoirs of the cell culture medium channels were loaded with EGM-2 media, and then 
the culture medium was aspirated at the other reservoir to fill media channels. Following 
loading all four reservoirs, the microfluidic platforms were incubated at 37 °C and 5% CO2. 
2.2.3 Fabrication of the microfluidic device 
The microfluidic device was fabricated with PDMS (poly dimethysiloxane, Sylgard 184, 
Dow Corning) using soft lithography and replica molding. The microfluidic device was 
modified from a previously reported device from our group. The channels were separated 
by micro-posts with 150 μm heights and 100 μm intervals. Slide cover glass (50 mm x 70 
mm, Matsunami) and PDMS were covalently bonded to each other by air plasma treatment 
(Fetmo Science). 120 μm thick structure was patterned on the silicon wafer by 
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photolithography with SU-8 150 photoresist (MicroChem). The PDMS base mixed with a 
curing agent at a ratio of 10:1 (w/w) was poured on the silicon wafer and cured for 3 hour 
on a 90°C hotplate. PDMS was detached from the wafer when fully solidified. Using 
biopsy punch 1 mm and 6 mm, cell injection ports and reservoirs for culture media were 
punched out. Gel injection port also punched out by biopsy punch 1mm; used for loading 
cancer spheroid and medium. After bonded, the device was stored in a 80 °C dry oven for 
3 days to be completely cured and to make its surface hydrophobic. 
2.2.4 CUBIC tissue clearing 
ScaleCUBIC-1 (reagent 1) was prepared as a mixture of 25 wt% urea (Nacalai Tesque Inc., 
35904-45, Japan), 25 wt% N,N,N’,N’-tetrakis(2-hydroxypropyl) ethylenediamine (Tokyo 
Chemical Industry CO., LTD., T0781, Japan), and 15 wt% polyethylene glycol mono-p-
isooctylphenyl ether/Triton X-100 (Nacalai Tesque Inc., 25987-85, Japan). ScaleCUBIC-
2 (reagent 2) was prepared as a mixture of 50 wt% sucrose (Nacalai Tesque Inc., 30403-
55, Japan), 25 wt% urea, 10 wt% 2,20,20’-nitrilotriethanol (Wako Pure Chemical 
Industries Ltd., 145-05605, Japan), and 0.1% (v/v) Triton X-100. To prevent loss of 3D 
blood vessels and spheroid information, we used CUBIC tissue-clearing protocols based 
on hydrophilic reagents that preserve fluorescence. After sample fixation, we introduced 
the CUBIC 1 solution into the medium channel for 1 week and conducted 
immunohistochemistry analysis. CUBIC 2 (RI-matching) solution was introduced 1 day 
before confocal imaging. 
2.2.5 Quantitative RT-PCR 
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RT-PCR quantitative analysis of HepG2, and HUVEC was conducted using an indirect 
transwell co-culture system. Total RNA was extracted from cells using TRIzol (Invitrogen) 
according to the manufacturer’s instructions. Complementary DNA was then synthesized 
from the extracted RNA using Superscript Ⅲ First-Strand Synthesis System (Invitrogen). 
Quantitative Real-time RT-PCR was performed with SYBR Green PCR Master Mix 
(Applied Biosystems, USA) using ABI 7300 Real time PCR system (Applied Biosystems, 
USA). Relative quantification of target mRNA expression levels was determined by 2(ΔΔ 
threshold cycle) (2−ΔΔCT) method. The expression level of each gene was normalized to 
GAPDH. At least three independent experiments were performed. The sequences of 
primers used are included in Table. 
Table 1. Primers used for qRT-PCR and RT-PCR. 
Genes Forward sequence Reverse sequence 
GAPDH TGATGACATCAAGAAGGTGGTG ACCCTGTTGCTGTAGCCAAAT 
PTEN CAGCCATCATCAAAGAGATCG TTGTTCCTGTATACGCCTTCAA 
P53 GGGTTGCAGGAGGTGCTTACGC TGCTGAGGAGGGGCCAGACC 
E-cadherin GCTGGACCGAGAGAGTTTCC CGACGTTAGCCTCGTTCTCA 
α-SMA CAAGTGATCACCATCGGAAATG GACTCCATCCCGATGAAGGA 
CXCR4 GGTGGTCTATGTTGGCGTCT ACACAACCACCCACAAGTCA 
CXCR7 GAGGCTCCTTTCTGCAGTGTAT TTCTGAGGCGGGCAATCAA 
CXCL12 AGATGCCCATGCCGATTCTT AAGGGCACAGTTTGGAGTGT 
VEGFR2 CGGTCAACAAAGTCGGGAGA CAGTGCACCACAAAGACACG 
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PECAM1 GTGCTGCAATGTGCTGTGAA GCTTGGTCCAAAATGCCTGG 
VE-cadherin CTTCACCCAGACCAAGTACACA AATGGTGAAAGCGTCCTGGT 
vWF CGTGGTCCTGAAGCAGACATA TTGCTGCTGGTGAGGTCATT 
VEGF-A ACGAAAGCGCAAGAAATCCC CTCCAGGGCATTAGACAGCA 
MCP-1 AGTCTCTGCCGCCCTTCT GTGACTGGGGCATTGATT 




The 3D reconstruction and cross section of the vessels were imaged using a confocal 
microscope (Olympus FV1000). The microscope and charge-coupled device (CCD) 
camera were controlled by MetaMorph (MolecularDevice, USA) software for time-lapse 
imaging. 
 
2.2.7 Permeability coefficient measurement 
To calculate the permeability coefficient, fluorescence images of FITC-dextran (10 kDa 
and 70 kDa) solutions were introduced into one of the two remaining media reservoirs. 
An open, perfusable microvessel allowed solution perfusion into the lumen. 10 x 
magnification pictures were obtained at 10 second interval over 10 min using time-lapse 
mode in FV1000.  
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The derivation process for this equation was detailed in a previous paper from our group 
[72]. The permeability coefficient P was derived using the equation below:  
P=1/IW ×(dI/dt)/Ij 
where IW is the length of vessel wall from the micropost that separates the microvessel 
from the perivascular region, Ij is the mean intensity in the microvessel region and I is the 
total intensity in the perivascular region. 
2.2.8 Statistical methods 
Prism (GraphPad, USA) was used for one-way ANOVA analysis with Tukey’s post-test. 
*** denotes p<0.001, ** denotes 0.001<p<.01, * denotes 0.01<p<0.05. For significant 
testing between two conditions non-paired student’s t-test as used. All data were 
expressed as the mean ± standard deviation (SD). 
2.3 Results 
2.3.1 Self-assembled 3D vascularized tumor spheroid model  
Tumor development occurs in two stages. When the tumor is relatively small, there is no 
development of neovessels yet to provide nutrients and oxygen to tumor cells; however, as 
the tumor grows, tumor cells stimulate ECs to initiate angiogenesis for tumor 
vascularization. The interaction between the tumor and blood vessels ultimately leads to 
the systemic spread of malignant tumor cells through the whole body (i.e., metastasis). To 
engineer a vascularized tumor spheroid (VTS) model at a chip level, we loaded a tumor 
spheroid and HUVEC suspension mixed with fibrin gel into the center channel of our VTS 
chip (Figure 2.1). We first demonstrated that the growth of the tumor spheroid within fibrin 
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matrix. Assessment of the spheroid growth in the device 5 days after implantation 
demonstrated significant growth of the spheroid (> 115%). Following HUVEC elongation 
at day 1, the formation of the vascular network and lumen structures were observed after 
3–4 days (Figure 2.2). Further development of the microvascular network (μVN) resulted 
in a densely interconnected microvascular system by day 5. To clearly present the 3D blood 
vessels and spheroid in our VTS chip, we applied CUBIC tissue clearing method that uses 
hydrophilic reagents to preserve fluorescence, allowing accurate 3D signal visualization 
and quantification of the vascularized tumor spheroid. This approach significantly 
increased z-direction penetration imaging depth (132 ± 19 to 384 ± 10 μm) while 
maintaining evenly distributed DAPI signals in the transverse direction (Figure 2.3).  
 
 
Figure 2.1 In vitro three-dimensional vascularized tumor model. Schematic 
representation of microfluidic design for in vivo like 3D vascularized tumor formation by 
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tumor spheroid and ECs mixture in the center channel under paracrine interactions with 
stromal fibroblasts in the outermost side channels. 
 
 
Figure 2.2 Bright field images of the development of vascularized tumor spheroid, 
composed of tumor spheroid enveloped by endothelial cells. White and yellow lines 
indicate tumor spheroid area. Scale bars, 200 μm. 
 
 
Figure 2.3 (A) Representative confocal images compare before (left line)/after (right 
line) clearing in the same sample. CUBIC tissue clearing does not lead to volume 
changes. Scale bars, 150 μm. (A, below) 3D reconstruction image of vascularized tumor. 
Tumor spheroid is enveloped by blood vessels. (B) Before/after clearing comparison of z 
axis imaging depth. (C) Before/after clearing comparison of xy plane relative intensity 
according to distance. (D) Before tissue cleared confocal image of vascularized tumor 
spheroid (left, top). After tissue cleared vascularized tumor spheroid (left, bottom) and 
3D reconstruction image of vascularized tumor spheroid (right).  
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2.3.2 Morphological and relative gene expression characterization of cancer only vs. 
cancer– EC hybrid spheroids  
We investigated the significance of cancer – EC co-culture in spheroid formation and 
relative gene expression change. We used HepG2 (human hepatocellular carcinoma) with 
human umbilical vein endothelial cell (HUVEC) cell lines to form the cancer specific 
hybrid spheroids. Spheroid formation and growth were investigated with varied cancer-to-
EC seeding ratios (cancer cells only, 4:1, 1:1, and 1:4) for a total of 5,000 cells. Tissue-
clearing by CUBIC allowed us to investigate spheroid volume, sphericity and HUVEC 
volume. In HepG2, the spheroid volume significantly decreased as the HUVEC ratio 
increased (1:1 and 1:4). The HepG2:EC 1:1 ratio spheroid exhibited the greatest sphericity, 
showing a significant morphological difference compared to the cancer-only spheroid 
(Figure 2.4A). The mixture of HepG2 EC spheroids showed that as the EC ratio increased, 
ECs tend to aggregate at the center of the spheroid. To further explore tumor–EC 
interaction, we examined the expression of tumor suppressor genes (PTEN and p53), 
epithelial-mesenchymal transition (EMT) markers (E-cadherin and alpha smooth muscle 
actin (α-SMA). When HepG2 cells were co-cultured with ECs by using Transwell, PTEN 
and p53 mRNA expression was significantly downregulated compared to the tumor 
monoculture, reflecting cancer aggressiveness, which plays a key role in the pathogenesis 
of human cancers in vivo. E-cadherin expression was significantly down-regulated, 
whereas SMA expression was significantly up-regulated in HepG2 compared to tumor 
monoculture controls (Figure 2.4B). This result indicates that HepG2 cells can increase 
their aggressiveness when co-cultured with ECs, causing a change in the signaling cascade. 
Furthermore, we investigated the expression of cytokine CXCL12 (stromal-derived factor 
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1ɑ) and its receptor CXCR4, which are a crucial axis in cancer tumorigenesis and 
progression. HepG2 co-cultured with ECs showed higher CXCL12/CXCR4 expression 
compared to the cancer mono-culture condition.   
To further investigate EC-cancer interaction, we checked EC angiogenic markers (vascular 
endothelial growth factor receptor 2 [VEGFR2], VE-cadherin, PECAM1, and VEGFA) 
using Transwell culture. When HUVECs were co-cultured with HepG2 cells, the relative 
mRNA expression of VEGFR2, VE-cadherin, and VEGFA were significantly upregulated 
compared to that of HUVEC monoculture. The mRNA expressions of CXCL12 was highly 
upregulated when co-cultured with HUVECs. In particular, von Wilebrand factor (vWF) 
expression was dramatically higher under both tumor co-culture conditions than in the 
HUVEC monoculture (Figure 2.5). 
 
Figure 2.4 Multicellular tumor spheroid characterization. (A) Representative confocal 
images of HepG2 – ECs spheroid with different cell ratio and spheroid sphericity of 
different cancer: EC ratios. All spheroid were fixed at day 5. (Scale bars, 100 μm. n=4-6). 
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(B) RT-PCR results of cancer cell monoculture and cancer cell co-cultured with ECs. 
Gene analysis considered markers 1) PTEN, 2) p53, 3) E-cadherin, 4) ɑ-SMA, 5) 
CXCL12 and CXCR4.The internal standard housekeeping gene was GAPDH. (n=3-4). 
 
Figure 2.5 RT-PCR results of ECs monoculture and ECs co-cultured with tumor 
(HepG2) at day 2. 
 
2.3.3 Angiogenic potential of cancer cell only vs. cancer– EC hybrid spheroid in the VTS 
model 
We next evaluated whether the effects of the cancer-EC hybrid spheroid on angiogenesis 
acceleration. HepG2-EC (1:1 ratio) hybrid spheroids significantly increased blood vessel 
volume compared to cancer-only spheroids, indicating that the cancer–EC hybrid spheroids 
accelerate angiogenesis and that this model may be useful for better modeling of the initial 
primary or micrometastatic stages of solid tumor progression (Figure 2.6).  
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Figure 2.6 Representative confocal images compared total blood vessel volume induced 
by vascularized tumor model of cancer cell only (HepG2) spheroid and cancer cells 
HepG2 – ECs spheroid. (Scale bars, 400 μm. n=4-6). 
2.3.4 Evaluation of vascularized tumor spheroid permeability 
Tumor vasculature is generally abnormal with aberrant branching and leaky vessel walls. 
Based on our previous findings (spheroid sphericity and volume and tumor marker 
expression), we decided to use a cancer-EC hybrid spheroid with 1:1 ratio in our next 
experiments. Especially, HepG2–EC hybrid spheroids exhibited highly interconnected 
microvessel networks and interactions between blood vessels and the tumor spheroid. 
Therefore, we used the HepG2–EC hybrid spheroid for further permeability and drug 
delivery experiments. Permeability coefficients were determined by introducing solutions 
containing fluorescein isothiocyanate (FITC)–dextran tracers into the vasculature (10 and 
70 kDa), and confocal imaging at 10-s intervals (Figure 2.7A). We then calculated apparent 
permeability, as described in the Methods. As shown in Figure 2.7B, the mean apparent 
permeability value of the vasculature only (with no tumor spheroid) was 1.80 × 10–5 cm/s, 
significantly lower than that of the HepG2-EC hybrid spheroid (5.93 × 10–5 cm/s). 
Interestingly, the addition of 50 and 100 ng/mL extrinsic tumor necrosis factor-alpha (TNF-
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ɑ) produced no significant difference (5.65 × 10–5 and 8.48 × 10–5 cm/s, respectively) when 
compared to HepG2-EC hybrid spheroid co-cultured condition (5.93 × 10–5 cm/s), but there 
was a significant difference when compared to the vasculature only; this suggests that TNF-
ɑ serves as a key factor in increased vascular permeability. In addition, when ECs were co-
cultured with HepG2 cancer cells, ICAM-1 mRNA expression was significantly 
upregulated compared to monoculture HUVEC, indicating that increased vascular 
permeability was closely related to ICAM-1 expression (Figure 2.7C). We then introduced 
70 kDa FITC–dextran tracers, a greater molecular weight than 10 kDa, into the vascular 
network. Permeability coefficient values decreased as the molecular weight of FITC–
dextran increased; this result was consistent with those of previous studies. The addition 
of 70 kDa FITC–dextran yielded no significant difference in the permeability coefficient 
between vasculature only and HepG2-EC hybrid co-culture model (Figure 2.7D). However, 
we observed focal intercellular openings in the vasculature, especially adjacent to the tumor 
spheroid (region of interest [ROI] 1; < 200 μm of the tumor spheroid boundary) (Figure 
2.7E). The number of intercellular openings significantly decreased when farther from the 
tumor spheroid boundary (ROI 2; > 200 μm from the tumor spheroid boundary). Thus, ECs 
located near tumor tissue, may have had loose interconnections, demonstrating the 
abnormality of tumor-associated vessels. Furthermore, we used 45 nm fluorescently-
labeled silica NPs to show NP transport and distribution throughout the vasculature using 
a syringe pump at 450 μL/h. NPs gradually filled and distributed throughout the vasculature. 
NPs penetrated through the endothelial pores, corresponding to focal intercellular openings 
in the vasculature, which is a hallmark of tumor associated vasculature (Figure 2.8). 
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Figure 2.7 Evaluation of vascularized tumor spheroid: permeability measurement and 
nanoparticle delivery. (A) Time series fluorescence micrographs were taken and analyzed 
for intensity changes in the perivascular region to measure permeability. After cell 
culture medium was removed, FITC-dextran (10kDa, 70kDa) solution was introduced 
and image were captured every 10 s. Red circles in bottom images represent focal 
intercellular openings (FIOs) (Scale bars, 100 μm) (B) The graphs shows permeability 
coefficient for 4 different conditions (10 kDa) (n=5-6). (C) The graphs shows 
permeability coefficient for two conditions (70 kDa). (D) qRT-PCR result of ICAM-1 
mRNA expression (n=3-4) (E) Number of focal intercellular openings. [ROI] 1; < 200 
μm of the tumor spheroid boundary and [ROI] 2; > 200 μm of the tumor spheroid 





2.3.5 Axitinib performance in the vascularized spheroid tumor model  
Next, we determined the antitumor and anti-angiogenic activities of Axitinib, a Federal 
Drug Administration (FDA)-approved drug, in our VTS model. Axitinib is a potent 
inhibitor of two receptors involved in angiogenesis: VEGFRs 1, 2, and 3, and platelet-
derived growth factor receptor (PDGFR). We administered Axitinib-containing media in 
the early and late stages of tumor vascularization and refreshed every 24 hours for 3 days. 
In the early stage, Axitinib was administered prior to formation of the 3D vascular network 
adjacent to the tumor spheroid (Figure 2.9A). We delivered 0, 1, and 10 nM Axitinib in the 
early stage of the tumor spheroid model (Figure 2.9B). The tumor spheroid area was not 
significantly different between vehicle controls with 1 and 10 nM Axitinib treatment 
(Figure 2.9C). However, Axitinib significantly reduced the blood vessel area and increased 
the number of disconnected blood vessels in a dose-dependent manner, indicating the anti-
angiogenic effect of Axitinib is reproduced in our model (Figure 2.9D and E). In contrast, 
when Axitinib was administered in the late stage (day 4) (Figure 2.9F), following 
vascularization, the area of the tumor spheroid was significantly smaller than vehicle 
control following 10 nM Axitinib treatment, demonstrating the antitumor activities of 
Axitinib (Figure 2.9G and H). This result may be attributed to the direct interaction 
between perfused blood vessels and the tumor spheroid. The blood vessel area was 
significantly decreased and regressed in a dose dependent manner under our experimental 
conditions, whereas the number of disconnected blood vessel between the control and 1 
nM Axitinib treatment group did not show a significant statistical difference. This result 
indicates drug resistance of tumor vasculature may serve as an irrigation system toward the 
tumor spheroid. In higher Axitinib dosage, blood vessels regressed and number of 
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disconnected blood vessel increased significantly compared to the vehicle control 
condition (Figure 2.9I and J). We note that the VTS chip could provide reliable and 
reproducible response of Axitinib treatment regarding spheroid size and blood vessel area 
monitoring, since the spheroid and EC gel mixture was gently loaded into center channel 
(Figure 2.10).  
 
Figure 2.8 Silica nanoparticle (NP) delivery through vasculature of vascularized tumor 
model at 3 time-points (top). Scale bars, 400 μm. Silica nanoparticle distribution at 




Figure 2.9 Antiangiogenesis and antitumor activities of Axitinib in VTS model. (A) 
Timeline of cancer drug treatment experiment. In the early stage of vascularized tumor 
model, Axitinib were introduced into the reservoirs a day after spheroid – ECs gel 
suspension injected to the central channel. (B) Representative confocal images show 
Axitinib dosage dependent response of spheroid and vasculature in the early stage of 
VTS model. Scale bars, 300 μm. Relative spheroid area (C), blood vessel area (D), 
number of disconnected blood vessel (E) in response to two different dosage of Axitinib 
(1 nM, 10 nM) at the early stage of VTS model. (F) Timeline of cancer drug treatment 
experiment. In the late stage of vascularized tumor model, Axitinib were introduced into 
the reservoirs 4 days after spheroid – ECs gel suspension injected to the central channel, 
which vasculature fully enveloped HepG2 – ECs hybrid spheroid. (G) Representative 
confocal images show Axitinib dosage dependent response of spheroid and vasculature in 
the late stage of VTS model. Scale bars, 300 μm. Relative spheroid area (H), blood vessel 
area per device (I), number of disconnected blood vessel per device (J) in response to two 
different dosage of Axitinib (1 nM, 10 nM) at the late stage of VTS model. 
 
 
Figure 2.10 Monitoring reliable and reproducible response of axitinib treatment. (A) 
Representative confocal images show 1 nM axitinib treated vascularized tumor spheroid 






2.3.6 Reconstituting lymphatic endothelial cell-blood vascular endothelial cell 
incorporated vascularized tumor spheroid in vitro  
Lymphatic and blood vessels form an intricate system during tumorigenesis. The 
generation of new lymphatic vessels through lymphangiogenesis and the remodeling of 
pre-existing lymphatics are considered as important steps in cancer metastasis. To further 
demonstrate the feasibility of our system in mimicking pathological vascularized tumor 
processes, we patterned EC–lymphatic EC (LEC) suspension (5 × 106 cells/mL each) with 
HepG2–ECs spheroids into the center channel. We observed physical interactions between 
the tumor spheroid and lymphatic and blood vessels. Both networks exhibited physical 
contact with tumor spheroids, enfolding the spheroid boundary (Figure 2.11). 
 
Figure 2.11 Confocal image of HepG2 – EC spheroid with lymphatic endothelial cells 




Current tumor-targeted drug-delivery systems are usually tested in xenograft mouse 
models. However, the data from these animal models often fail to reproduce the results in 
clinical studies. This translation issue is believed to be the phylogenetic difference between 
human and animal models. This absence of correlation has underscored the importance of 
developing alternative approaches ways to better predict the clinical efficacy. Recent 
advances in the microengineering of TME using organ-on-a-chip technologies have 
enabled the development of pathophysiologically relevant human tumorigenesis models. 
Solid tumors are composed of tumor and stromal cells (vascular, fibroblast and immune 
cells) and ECM components in a highly interactive 3D microenvironment characterized by 
cell–cell and cell–ECM interactions, as well as local gradients of nutrients, growth factors, 
and oxygen [73]. The tumor stroma consists of non-tumor cells (e.g., fibroblasts, tumor-
associated fibroblasts, endothelium, and immune cells) and a highly cross-linked fibril-like 
ECM structure with collagen and fibrin as its major constituents [74]. 
The tumor spheroid resembles a small tumor mass in its morphology, growth kinetics, cell–
cell and cell–matrix interactions, and nutrient transport. Therefore, the tumor spheroid can 
serve as an excellent in vitro 3D tumor model.  
Our results show that multicellular spheroids composed of tumor cells and ECs 
downregulated tumor suppressor gene and epithelial E-cadherin mRNA expressions. These 
results are consistent with those of several studies reporting such gene expression changes 
in association with tumor–EC interaction [75, 76]. Co-culture of tumor cells and ECs 
causes reprogramming of the signaling within and between the two cell types [77]. 
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Furthermore, we demonstrated that the cancer HepG2–EC hybrid spheroid significantly 
enhanced angiogenesis compared to mono-cultured cancer spheroid. Our RT-PCR results 
suggest that the cancer–EC spheroid alters the molecular and cellular factors that drive 
angiogenesis. Thus, we demonstrated that the co-culture of cancers with ECs is required 
for accurate modeling of aggressive tumors in vitro. Multicellular hybrid spheroid will 
allow for more accurate modeling of the initial primary or metastatic stages of solid tumor 
progression than those with cancer cells only. 
A main challenge of the conventional tumor spheroid models is the lack of vasculature 
adjacent to tumor spheroid. Through microengineering, we successfully incorporated 
tumor spheroid associated vasculature at the chip level. Our VTS on a chip model allowed 
us to investigate the interaction between ECs and the tumor spheroid. This model captured 
some of the complexity of in vivo tumors, including the 3D spheroid structure, EC 
vascularization, stromal fibroblasts, ECM, and nutrient and drug delivery via a 3D perfused 
vascular network. Our VTS model was able to simulate the vascular network in response 
to physiological cues from the tumor spheroid. To establish VTS, we loaded a tumor 
spheroid–EC suspension mixture within the fibrin matrix into a microfluidic channel. ECs 
self-assembled into the vascular network, forming complex structures interacting with the 
tumor spheroid.  
To clearly obtain 3D in-depth confocal imaging of our model, we used the tissue-clearing 
CUBIC technique [78] to overcome the physical constraints imposed by light scattering 
and the subsequent challenge to mimic this complex biological system in a native 3D 
context. The CUBIC protocol uses basic aminoalcohol-based cocktails in addition to urea 
and Triton X-100 to enhance its clearing capability [79]. The benefits of this method 
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include the use of nontoxic reagents and ease of implementation. We introduced the 
clearing solution into the medium channel, allowing diffusion toward the spheroid. In the 
CUBIC-treated microfluidic chip, general VTS morphology was well-maintained at the 
cellular and subcellular levels, despite high lipid losses within the tissue.  
One manifestation of tumor vessel abnormality is such defective and leaky endothelium 
that are disorganized and irregularly shaped with focal intercellular openings [80]. In 
addition, the vascular basement membrane has an abnormally loose association with ECs 
and pericytes. These physical characteristics together with cytokine (e.g., VEGF) 
production are responsible for elevated macromolecular permeability, leading to potential 
coupling between intravascular and interstitial flow [81]. Due to high pro-angiogenic 
signaling, the network of tumor-associated blood vessels is chaotic, with loose inter-
endothelial cell junctions. The resulting leaky and collapsed/narrowed vessels lead to low 
perfusion and starve some tumor regions of nutrients. Our models with HepG2 showed 
distinct angiogenic behaviors; the HepG2–EC hybrid tumor spheroid produced a 
perfusable vascular network, whereas the U87MG–EC hybrid tumor spheroid showed poor 
vascular perfusion, demonstrating tumor-specific vascularization characteristics (Data not 
shown). When 70-kDa FITC–dextran was introduced into the HepG2–EC tumor spheroid 
model, we observed focal intercellular vascular openings especially adjacent to the tumor 
spheroid and the subsequent increase in the extravasation of NPs > 40 kDa due to the high 
tumor vessel permeability [82]. In the presence of vascular pores 200–1,200 nm in size, 
the fenestrated neovascular wall enhanced vascular permeability, resulting in increased 
drug accumulation in the tumor [83] indicating that these endothelial gaps or transcellular 
holes could explain the leakiness of tumor vessels [84]. Furthermore, we were able to 
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demonstrate real-time observation of NP delivery and transport through adjacent 
vasculature of the tumor spheroid in our model under pathophysiological flow conditions. 
This approach may provide a useful platform to test drug-loaded NP delivery to the tumor 
through vascular endothelial barriers. 
As new cancer drugs are introduced for cancer treatment, and as an increasing number of 
candidates progress through preclinical and clinical development, it is important to 
improve our understanding of the effects of cancer drugs on tumor blood vessels and tissues 
[85]. Axitinib is a small-molecule oral tyrosine–kinase inhibitor (TKI) that is a more 
selective and potent inhibitor of VEGFR 1, 2, and 3 than many other clinical anti-
angiogenic agents [86]. Inhibitory concentrations of Axitinib are 0.1 nM for VEGFR1, 0.2 
nM for VEGFR2, and 0.1-0.3 nM for VEGFR3, whereas anti-PDGR activities and anti-Kit 
activities are nearly 10 times weaker (IC50: 5 nM for PDGFRɑ, 1.6 nM for PDGFRꞵ, and 
1.7 nM for Kit) [87]. It was also confirmed that Axitinib had dose-dependent inhibitory 
effects on angiogenesis and tumor growth including xenograft model of human tumors: 
Axitinib induced regression of the tumor vasculature, with loss of endothelial sprouts and 
decreased vessel density. We successfully confirmed theses effects in our VTS model. 
 We demonstrated that Axitinib significantly decreased tumor spheroid growth at a high 
dose (10 nM) when administered via vascular network after vascularization. This finding 
implies that our VTS models promote cellular interaction with Axitinib, resulting in the 
suppression of tumor progression and growth, which corresponds to previous xenograft 
and clinical studies [88, 89]. More importantly, our model confirmed dose-dependent 
inhibition of angiogenesis by Axitinib before and after tumor vascularization. In particular, 
Axitinib caused tumor vasculature regression, with a loss of endothelial sprouts and 
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fenestration and a decrease in vessel density. Of note, after vascularization, even though 
we administered specific amount of Axitinib (1 nM), tumor spheroid associated blood 
vessels still served as a perfused tumor vasculature network, indicating necessity of higher 
dosage treatment of anti-angiogenesis drug to regress tumor vasculature. Overall, our VTS 
model may offer a promise approach to accelerate the clinical testing of large number of 
cancer drug candidates.  
We though note that our vascularized tumor model could not recapitulate interconnection 
or penetration of the surrounding vasculature. Tumors can induce ECs to form new supply 
lines to a tumor during angiogenesis. Blood vessels grow into the tumor mass to supply 
nutrients and oxygen to rapidly dividing cancer cells. There is another way to feed a tumor, 
namely vasculogenic mimicry, in which cancer cells form blood-carrying channels; this 
process can supplement traditional angiogenesis [90, 91]. In this manner, tumor 
surrounding vessels hook up to channels within the tumor mass. Potential improvements 
to current models include the introduction of blood vessel growth into, or hook up to 
channels within, the tumor mass. However, challenges remain in reconstituting the fully 
functionality of vascularized tumor tissue. 
2.5 Conclusion 
We engineered a micropathological system of an in vitro 3D perfusable vascularized tumor 
spheroid model that exhibits the pathologically relevant structure with high reproducibility. 
We first analyzed the morphological characteristics of a cancer–EC spheroid mixture with 
varying cancer cell to EC ratios. When cancer cells were co-cultured with ECs, RT-PCR 
gene expression analysis showed that the cancer cells were highly aggressive. Microfluidic 
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experimental and RT-PCR results showed that cancer–EC spheroids had greater pro-
angiogenic behavior than cancer cell-only spheroids. Our VTS model also exhibited leaky 
and fenestrated vasculature, which is a hallmark of tumor vasculature. Finally, we 
demonstrated a proof-of-concept application of the model for drug screening with varied 
dose and treatment timing, which is critical to screen drugs and fine their compositions for 
the treatment of heterogeneous tumors. With patient-derived multicellular tumor spheroids 
introduced to our VTS model, this approach may bridge highly specific human in vitro 
cultures and pathophysiological in vivo conditions to promote the study of tumor biology 
in the context of personalized precision medicine and immunotherapy. 
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CHAPTER 3. INJECTION-MOLDED 3D CULTURE 
PLATFORM: VASCULARIZED TUMOR SPHEROID CULTURE 
3.1 Tumor Spheroid-on-a-chip: a Standardized Microfluidic Culture Platform for 
Investigating Tumor Angiogenesis 
In vitro model systems drive biological studies by replicating human body processes and 
functions from the molecular to the whole organism level [92]. The human body is 
composed of both cellular and non-cellular components which are organized in a highly 
specialized manner [55]. However, it is difficult to mimic all the features of human biology 
with one in vitro model system. 3D cell culture systems have demonstrated many important 
advantages over 2D cell culture systems; 3D models more accurately mimic the complex 
in vivo microenvironment and produce cellular behavior which is closer to natural 
conditions [2]. 
In the area of cancer research, although tumors are complex 3D structures with their own 
distinct microenvironments, many conventional 2D culture studies ignore this complexity 
for convenience and simplicity [93, 94]. However, recent advances in engineered TMEs 
using microfluidics technology have enabled researchers to mimic physiologically relevant 
3D TMEs [95], such as tumor angiogenesis [96], tumor metastasis [26], and tumor–stromal 
interaction [97]. Of note, 3D tumor spheroid models have been highlighted and have drawn 
attention for their potential applications in anti-cancer drug screening. Distinct from those 
of 2D cultures and biopsy samples, multicellular spheroids can provide proliferative 
gradients, reduced drug and gas exchange, and cell–cell and cell–ECM interactions which 
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are essential characteristics of a solid tumor microenvironment. However, without an 
appropriate in vitro model system, it has been impossible to observe tumor spheroid 
induced angiogenesis, which is an essential characteristic of the solid tumor 
microenvironment [63]. 
The Sphero-IMPACT is designed as a mass-producible injection-molded polystyrene (PS) 
device in a standardized 96-well plate SBS format. 3D printing and injection molding have 
enabled the rapid prototyping of platform designs to scale up production. Based on an 
understanding of open microfluidics, a platform utilizing geometrically modeled 
spontaneous capillary flow has been announced as having potential for a robust and 
reproducible liquid patterning tool [98]. Our previous publications debuting the IMPACT 
platform focused on the fabrication, fluid patterning mechanism and 3D vasculature 
formation assay with various patterning and culture conditions [52]. In this work, we 
propose a newly Sphero-IMPACT specialized in a 3D tumor spheroid culture assay with 
vasculature. The Sphero-IMPACT provides monitoring of vasculogenesis, angiogenesis, 
tumor cell migration and invasion from the spheroid and investigates the effect of 
anticancer drugs on angiogenesis induced by tumor spheroids. 
This work describes a straightforward design that involves a hole in the middle of the rail 
to pattern a large spheroid (up to 800 μm) together with an extracellular matrix (ECM) as 
compared to previous publications. The tapered hole can accommodate pipette tips and 
allow one-step patterning of a spheroid in the region of interests with a highly reproducible 
manner. This standardized, plastic-based microfluidic platform is fully compatible with 
automated dispensing systems and automated microscopes. In addition, a mass-producible 
injection molded platform can provide a higher degree of uniformity per device due to the 
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lack of human manual labor steps. Such an approach also allows for the accessibility of 
higher throughput experimentation with less time and effort. 
Our platform is designed to be easy-to-use by all experimenters and simple to use without 
complicated pre-treatment. By applying a lung fibroblast (LF) laden hydrogel in the center 
rail channel and attaching human umbilical vein endothelial cells (HUVECs) at the side of 
the center rail channel, we were able to observe robust angiogenic sprouting patterns with 
a different LF-hydrogel patterning volume. Also, we demonstrated that the tumor cell 
spheroid (brain glioblastoma, U87MG) invasion area increased by adding extrinsic 
transforming growth factor beta 1 (TGF-β1) and tumor necrosis factor alpha (TNF-α), 
demonstrating the ability to place the spheroid in the region of interests within our platform 
for direct observation. We further demonstrate the applicability of the platform to 
vascularization by introducing the tumor spheroids (sized 500–600 μm), providing 
physiologically relevant mimicry of 3D TMEs for anticancer drug efficacy testing. Our 
Sphero-IMPACT can potentially provide a cost-effective HTS platform with a 
physiologically relevant microenvironment for vascularized cancer biology and 
vascularized cancer drug screening. 
3.2 Materials and Methods 
3.2.1 3D printing for prototypes 
Sphero-IMPACT was tested through 3D printing prior to injection molding. A prototype 
of Sphero-IMPACT was fabricated by a DLP type 3D printer (Perfactory mini 4, 
EnvisionTec) with the ERM (Enhanced Resolution Module) system. 3D printed models 
were rinsed with isopropyl alcohol for 20 min and post cured by 385 nm UV for 30 min. 
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For surface modification and biocompatibility, poly(c-xylene) was deposited with a 
thickness of 5 μm by plasma enhanced CVD (Lavida, Femtoscience). 3M™ 9795R 
advanced polyolefin diagnostic microfluidic medical tape (thickness: 50 μm) as the 
substrate for the chip is bonded to the 3D printed body part to complete the device. This 
tape is adhesive type coated with silicone acrylic, so it can be pressed and pasted. 
3.2.2 Fabrication of Sphero-IMPACT 
Polystyrene (PS) injection molding was performed at an R&D Factory (Korea). The 
aluminum alloy mold core was processed by machining and polishing. The clamping force 
at the time of injection was set at 130 tons with a maximum injection pressure of 55 bar, 
15 seconds of cycle time, and a 220 °C nozzle temperature. The substrate was bonded to 
the injection-molded PS part to complete the device. The 3d printed spheroid chips and 
alloy mold core were designed by Solidworks, Dassault systems. 
3.2.3 Cell Culture 
Human umbilical vein endothelial cells (HUVECs, Lonza) were cultured in endothelial 
growth medium (EGM-2) and passage 4 was used for the experiments. Red or green 
fluorescent proteins (RFP and GFP) expressing HUVECs were obtained from Angio-
Proteomie (Boston, MA). Normal human lung fibroblasts (LFs, Lonza) were cultured in 
fibroblast growth medium (FGM-2, Lonza) and passage 6 was used for the experiments. 
Human glioblastoma cells, U87MG (a gift from Dr Sun Ha Paek at Seoul National 
University) and human hepatocyte carcinoma cells (HepG2, Korean Cell Line Bank) were 
cultured in DMEM supplemented with 10% FBS, penicillin (100 U ml−1) and streptomycin 
(100 U ml−1). All cells were maintained in a humidified incubator at 37 °C and 5% CO2. 
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3.2.4 Retrovirus production and transfection 
The retroviral plasmid vector carrying GFP was purchased from Addgene. Retroviruses 
expressing GFP were obtained by transfecting a mixture of viral plasmid and retroviral 
packaging plasmids (gag/pol expressing vector, and VSV-G envelope vector) into HEK 
293FT cells using Fugene 6 transfection reagent (Roche, Basel, Switzerland). 24 hours 
after transfection, the medium was replaced by fresh medium and viral supernatants were 
harvested at 48 and 72 hours. After filtration through a 0.45 μm filter with a PVDF 
membrane (Pall Life Sciences), HepG2 and U87MG were infected with retroviruses in the 
presence of polybrene (Sigma). 24 hours after infection, the cells were washed with PBS 
three times and expanded in growth medium. 
3.2.5 Spheroid preparation 
U87MG, the glioblastoma multiforme (GBM) spheroid was grown in a 96-wellplate with 
U-shaped bottom wells (Sumitomo Bakelite, Tokyo, Japan). The U87MG cell suspension 
was prepared for a total of 5000 cells per well and mixed with a 1% volume ratio of 
Matrigel. After pre-culturing in a U-shaped 96-wellplate for 4–5 days, a spheroid was 
introduced into the Sphero-IMPACT for tumor migration & invasion assay and tumor 
angiogenesis evaluation. For the LF spheroid, the LF cell suspension was prepared for a 
total of 10,000 cells per well and a mixed 1% volume ratio of Matrigel. FGM-2 was used 
to maintain the LF spheroid for 4–5 days. 
3.2.6 Immunostaining 
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For immunofluorescence staining, cells in the device were fixed using paraformaldehyde 
(PFA, 4% w/v in PBS) for 15 min, permeabilized with Triton X-100 (0.1% v/v in PBS) for 
30 min, and then blocked in bovine serum albumin (BSA, 3% w/v in PBS) for 1 h at room 
temperature. Endothelial cells were marked using Ulex europaeus agglutinin 1 (VECTOR, 
USA). Phalloidin (Alexa Fluor 594) and Hoechst 33342 were purchased from Molecular 
Probes. 
3.2.7 Migration, invasion and tumor spheroid-induced angiogenesis assay 
The 4–5 days cultured U87MG spheroid was collected from U-shaped 96-well plates. 
Using a 200 μL pipette tip, a tumor spheroid was mixed with a 2.5 mg mL−1 concentration 
of fibrinogen solution. The spheroid and fibrinogen solution were mixed with thrombin 
(0.5 U mL−1, Sigma) and then immediately introduced into the central channel of the device. 
Since the spheroid (>500 μm) is greater than the channel height (100 μm), the spheroid was 
set to be stationary at the bottom of the channel. For tumor spheroid angiogenesis assay, 
the tumor spheroid and LF cell suspension at a concentration of 1 × 106 cell per mL were 
mixed with fibrinogen solution and mixed with thrombin. Next, the spheroid-cell-
fibrinogen suspension was immediately introduced into the central channel of the device. 
We seeded additional HUVECs in both the media reservoirs and incubated them for 20 
min to adapt to the surface of the fibrin gel. Next, we introduced EGM-2 media or cancer 
drug containing media for subsequent experiments. 
3.2.8 Drug testing 
For the monoclonal antibody drug, cetuximab (a gift from Dr. Jo) was diluted to 1 mg mL−1 
with EGM-2 and bevacizumab (a gift from Dr. Jo) was used in 1 mg mL−1 concentration 
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in EGM-2. Each antibody drug was introduced to the media reservoir. For the inhibitors, 
sunitinib was dissolved in DMSO according to the manufacturers' instructions and added 
to cell culture media at a concentration of 1 μM. 
3.2.9 Imaging and data quantification 
The 3D reconstruction and cross section of the vessels were imaged using a confocal 
microscope (Olympus FV1000). The microscope and charge-coupled device (CCD) 
camera were controlled by MetaMorph (MolecularDevice, USA) software for time-lapse 
imaging. To quantify the vascular area coverage during angiogenesis blood vessel 
formation and tumor migration and invasion assay, z-projections of the 3D stacks images 
were obtained using ImageJ (NIH) and the proportion of the fluorescent pixels within the 
ROI of each image was calculated. The length of angiogenic sprouting and tumor cell 
migration & invasion were determined by manually measuring the distance from the 
original gel and spheroid interface.  
3.2.10 Statistical analysis 
Using Prism (GraphPad, USA), statistical comparisons of the values were obtained from 
an unpaired two-tailed Student's t-test analysis, with the threshold for statistical 
significance set at *p < 0.1. **p < 0.01; ***p < 0.001; ****p < 0.0001; and ns (not 
significant). The standard error of the mean (SEM) is presented in error bars. 
3.3 Results and Discussion 
3.3.1 Sphero-IMPACT design optimization and considerations 
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Sphero-IMPACT is a means to illuminate a more complex microphysiological system. This 
3D cell culture array is designed to be able to introduce a cell spheroid, enabling more 
diverse assays for vascularized tumor models. The platform is designed to be highly 
compatible with most types of laboratory equipment (e.g., microscopes, automated 
dispensers) and has a 96-well plate specification to increase its value (Figure 3.1). The 
platform consists of a rail guide for cell patterning region and media reservoir each side. 
The cell patterning region contains a single hole in the center, designed to capture a large 
spheroid. As shown in Figure 3.1B, the tapered hole has a diameter of 0.83 mm and draft 
of 4.0 degrees, so that it fits a 200 μl pipette tip with a diameter of 0.9 mm. Then, the pipette 
tip completely seals the hole so that the tumor spheroid and hydrogel can be patterned in 
the channel in a single step without leaking. The medium reservoir is separated by a 5.0 
mm wall in the center, which enables us to use different volumes of conditioning medium 
in each channel (Figure 3.2). Novel fabrication methods should be developed to increase 
the flexibility of microfluidics. 3D printing has recently emerged as an alternative 
microfluidics manufacturing method and has been demonstrated to be a potential solution 
to the problems associated with PDMS-based manufacturing methods [99]. This rapid 
prototyping requires just one step, in comparison to soft lithography, which requires several. 
The single step is to transfer a file prepared by computer aided design (CAD) software to 
the 3D printer and then wait for the output. Moreover, 3D printing has many advantages in 
terms of maximizing design flexibility, with convenience of optimization [99]. Concerning 
the design process, it enables users to change any component, for example ones that require 
modification for optimization purposes, using CAD software and is simple and easy to run 
[100]. We developed the Sphero-IMPACT using a following rapid prototyping process 
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involving fluid patterning and design optimization for 3D multiple cell culture (Figure 3.3). 
To deploy a 3D culture for cancer drug discovery and screening, we developed a 
standardized microfluidics platform Sphero-IMPACT with the following characteristics: 
(1) a 96-well plate SBS format-based design with fully automated imaging; (2) a single 
spheroid per well, centered for ease of imaging; (3) an HTS angiogenesis assay; and (4) 
uniform culture conditions for quantitative assessment of various cancer drugs. Although 
3D printing has many advantages, it has throughput issues because its production rate is 
limited based on the specification of the equipment [101]. We achieved faster production 
by injection molding the final design. We adopted a PS quick delivery model (QDM) for 
injection molding to achieve greater conformity, transparency, and productivity [102]. 
Unlike other mass production techniques, as the mold core is made of aluminum alloy, 
QDM only provides about 3000 guaranteed shots. Hence, it can play an intermediate role 
between prototyping and mass production. As shown in Figure 3.1A, we designed a 
microchip array based on the SBS format which reflected a 9 mm pitch in the horizontal 
axis, and an 18 mm pitch in the vertical axis. Each unit configured reservoirs for media 
supply and a rail guide which includes a hole. In our actual cell culture experiment, we 
produced eight spheroid culture units in one chip, which fit onto a commonly used slide 
glass size (75 mm × 2 5 mm), as well as into the 96-well plate format. These properties are 
compatible with conventional automation cell culture systems and confocal microscopy 
systems, and thus raise the possibility of high-throughput drug screening. 
 53 
 
Figure 3.1 Design of the standardized microfluidics platform for tumor spheroid-on-a-chip. 
(A) A conceptual image of Sphero-IMPACT based on a standard 96-well plate format. (B) 
Sphero-IMPACT has a media reservoir on each side, centered on a fluid rail guide for cell 
culture. The rail guide contains a tapered hole functioned as a culture space for a cell 
spheroid. (C) Spontaneous fluid patterning by capillary action. Fluid can be transferred 
simply and robustly along the rail guide under hydrophilic condition. (D) The patterned 
fluid configures a concave meniscus at the edges of the structure. A fluorescence image 
showing GFP-expressing HUVECs patterned with fibrin gel which forming the meniscus, 
and RFP-expressing HUVECs seeded on the reservoir. (E) The cross-sections of the 
devices filled with a solution of Rodamin B under noted volume were converted to 
grayscale images for analysis. White dash lines indicate the fluid rail guide, and yellow 




Figure 3.2 Overall schematics of the structural components of tumor spheroid-on-a-chip. 
(A)Illustration of 96-well plate SBS format-based microplate. (B) A single array of 
tumorspheroidon-a-chip as a prototype model. (C-D) Schematic view detailing the 




Figure 3.3 Process schematic of Sphero-IMPACT design optimization with 3D printing 
for mass production through injection molding. (A) 3D printing prototypes allow for rapid 
dimensional testing and optimization prior to high investment but high yield injection 
molded production. (B) During the process, we performed the platform validation through 
fluid patterning and cell culture testing. This process was approached through the trial and 
error method. (C) Once a design has been configured for injection molding, the design can 
be mass produced for easy accessibility for the end user. 
3.3.2 Gel patterning principle  
The proposed device is based on a different fluid patterning approach to that used in 
conventional PDMS chips. Fluid guide structures allow fluids to be easily transported 
spontaneously by capillary forces in a hydrophilic environment. Hence, structures can be 
designed to engineer capillary flow patterns [103, 104]. Important conditions for the 
patterning to work reliably is to have hydrophilic surfaces (contact angle <25°) and an 
adequate gap between the structure and substrate (<500 μm). The width of the structure is 
not critical [98]. We mainly considered the height from the substrate as the key factor 
influencing the patterning conditions. The channel depth from the substrate is 100 μm, so 
the device can transport fluid into the zone. The channel and substrate were hydrophilized 
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by plasma treatment to ensure that the contact angle was 0 degrees. Fluid exposed to this 
surface will trigger a capillary action when it encounters the rail guide structure. The fluid 
then formed concave meniscus between the edge of the structure and the substrate. Such 
an affinity environment for fluid patterning is significant in that it can acquire smooth fluid 
interfaces as well as spontaneous fluid transport (Figure 3.1C). We patterned the identical 
volume (4.0 μl) of fluid in both hydrophilic and hydrophobic conditions. In the 
hydrophobic environment, the interface of the fluid showed a surface imbalance due to the 
resistance of the rail guide structure. On the other hand, we visually confirmed that the 
fluid was well-patterned according to the guide structure in a hydrophilic environment 
(Figure 3.4). Based on this result, we applied this concaved meniscus surface as an 
additional cell culture region. First, we patterned GFP-expressing HUVECs with fibrin gel 
in the structure; then, we seeded suspension included RFP-expressing HUVECs onto the 
surface (Figure 3.1D). This approach has traditionally been considered as a way of 
resolving the issues presented by tilting the device to attach cells to the 3D gel surface. The 
RFP-expressing HUVECs were able to migrate towards the fibrin gel due to the growth 
factor surrounding the gel. The shape of this curved surface has been shown to vary with 
the volume of fluid injected. To assess the dependence of the geometry of the curved 
surface on the injection volume, Sphero-IMPACT was filled with rhodamine B solution 
volumes of 2.0, 4.0, 6.0 and 8.0 μl. The cross-section of the patterned area obtained from 
the imaging platform was converted into a grayscale image to distinguish the outlines of 
each surface. The converted images were analyzed by tracing the curvature with a yellow 
dashed line and the fluid guide structure with a white dashed line. We proceeded to explore 
the meniscus formed between the fluid guide structure and the substrate by the filled fluid 
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according to each volume (Figure 3.1E). Due to the larger curvature, the gentle interface 
of the gel makes cell seeding simpler than conventional methods. In previous studies, 
particularly with the PDMS-based chip, the meniscus caused by the hydrophobic 
environment was convex, which forced the cells to tilt more than 30 min at an angle of 90 
degrees to be located on the gel interface. 
The geometry of the interface between the hydrogel and the cell culture medium is 
important because the amount of additional endothelial cells that are injected into the 
medium reservoir in the cell suspension form depends on the radius of the curvature of the 
interface. In our tumor angiogenesis experiments, endothelial cells were only patterned in 
the medium reservoir. As shown in Figure 3.1E, the radius of the curvature increases with 
the injection volume, but decreases when the volume reaches 8.0 μl. This is due to the 
excess suspension flooding the wall of the central channel. Many other 3D vascularization 
platforms have been introduced, including additional procedures for placing endothelial 
cells on the hydrogel surface, such as surface coating [105] or gravity-driven attachment 
[106]. We attached endothelial cells to the patterned hydrogel using a fluid interface 
formed from a hydrophilic surface. Upon seeding, HUVECs form a monolayer as they 
reach confluency at the gel–media interface. Both the area of the vascular network and the 
number of sprouting volumes increases until the injected volume reaches 6.0 μl, then 
decreases when the volume reaches 8.0 μl. This shows that maximizing the radius of the 
curvature of the interface is key to enhancing the proliferation and efficiency of cell 
attachment, without requiring any additional treatment or procedures. This approach not 
only ensures the convenience of the experimenter but also reduces the variability of the 
results since there is no additional procedure. Sphero-IMPACT allows users to experience 
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a variety of assays based on intuitive design and usage. Here, we presented well-performed 
assays for vasculogenesis, angiogenesis, tumor migration and tumor spheroid-induced 
angiogenesis (Figure 3.5). 
 
Figure 3.4 Fluid patterning under the hydrophilic and hydrophobic environment. 
(A)Investigation of the contact angle of the material used in the device under hydrophilic 
conditions to establish the fluid patterning technique. (B) The fluid interface showed 
surface imbalance under hydrophobic environment. After the plasma treatment, the fluid 
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was well patterned under hydrophilic environment. 
 
 
Figure 3.5 Various in vitro model approaches of Sphero-IMPACT. (A) Vasculogenesis; 
the platform can perform co-culture modeling to develop a 3D perfusable blood vessel 
networks. (B) Angiogenesis; induction of directional angiogenesis by attaching HUVECs 
to patterned fibrin gel-meniscus in a rail guide structure. (C) Tumor migration assay; ease 
of experimentation and observation through the space for a spheroid inside the platform. 
(D) Tumor spheroid-induced angiogenesis; construct tumor model which is vascularized 
through co-culture of tumor spheroid and blood vessel. 
3.3.3 Angiogenesis assay 
A wide and diverse variety of models have been actively developed for developmental and 
pathological angiogenesis[19, 107, 108]. Preexisting microfluidic platforms have adopted 
soft lithography with replica-molding using PDMS. The advent of the PDMS based 
microfluidic platform allowed for unprecedented control regarding cell patterning and 
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physiologically relevant 3D microenvironments with a reduction in the cell and media 
requirements. Moreover, several studies using this microfluidic platform have been 
reported recreating TME and angiogenesis in vitro. Although it has shown meaningful 
results, some of the disadvantages of the platform have lowered the possibility of being 
practically used. 
Compared to the PDMS-based hydrophobic burst valve design, this work utilized the 
hydrophilic liquid guide to obtain rapid and reproducible patterned gels for 3D cell cultures. 
When a liquid drop is placed on the device, spontaneous patterning is achieved in a 
reproducible manner. Compared to injection molding, the soft lithography based PDMS 
chip has a remarkable low production efficiency. There are additional manual steps such 
as curing, cutting and mixing, which is labor-intensive. However, in the case of injection 
molding, a large quantity of devices can be produced quickly, so the experiment can be 
carried out with ready-to-use devices (Figure 3.6). And, for the angiogenesis assay, the 
interface of this patterned gel forms a concave meniscus, which provides a beneficial 
advantage for placing cells on the gel. In previous studies, the angiogenesis assay had to 
be supplemented with a tilting of the device at an angle of 90 degrees for more than 30 
min.38 We used a fluid meniscus to simplify this step. It is important to devise a method 
to place endothelial cells close to the matrix using a single gel patterning step. We patterned 
LFs with fibrin gel as a growth factor supplier, to induce angiogenesis underneath the 
structure. After the gel was cross-linked, HUVECs were exposed in suspension around the 
gel surface. Of the exposed HUVECs, the cells placed on the gel sprouted into the matrix 
over time (Figure 3.7A and B). Based on this outcome, we decided to study angiogenesis 
in terms of the amount of hydrogel, while taking into account the co-culture conditions of 
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the tumor spheroids. Angiogenesis modeling was performed under four patterning volume 
conditions, with identical concentrations of fibrin gel and LFs (Figure 3.7C and D). The 
morphologically quantified results showed that the sprouts were vigorous and uniform 
under 6.0 μl volume conditions. In the case of 2.0 μl, the HUVEC was not evenly placed 
due to the lack of volume of fibrin gel under the structure, resulting in uneven vascular 
sprouting. On the other hand, when filling up 8.0 μl of fibrin gel, the gel covered the edge 
of the fluid guide structure due to overfilling. As a result, the gel interface became so steep 
that placement of HUVECs was difficult. We introduced fluorescence microparticles in the 
media reservoirs of cultured samples at 6.0 μl volume conditions to demonstrate the 
perfusable characteristics of the blood vessels (Figure 3.7E). The center hole in the fluid 
guide structure can be filled up additionally as the volume of the LF embedded fibrin gel 
increases. This appearance can result in a larger amount of VEGF concentration than in the 
surrounding environment. Furthermore, it can induce vigorous growth of surrounding 
blood vessel cells. We focused on a preceding study that angiogenesis can occur actively 
near the central hole area and tried to show the effect in a different way by inserting the LF 
spheroid into the hole. We observed vasculogenesis by forming GFP-expressing HUVEC 
around the spheroids. The model cultured for 4 days showed that vasculogenesis was more 
active around the hole through F-actin staining (Figure 3.7F). 
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Figure 3.6 A diagram comparing the time required for production of the device between 





Figure 3.7 Engineered 3D perfusable blood vessel networks in Sphero-IMPACT. (A) An 
illustration of angiogenesis model configuration in Sphero-IMPACT. (B) A cell culture 
approach to construct angiogenesis model. (C) Investigating an optimal patterned volume 
for inducing effective angiogenic sprouts. Every sample was cultured for 5 days and stained 
with lectins (green) as markers of endothelial cells. Scale bar = 1000 μm. (D) The total 
vascular network area and the number of vessel sprouts were quantitatively evaluated to 
determine appropriate conditions for angiogenesis depending on the patterning volume. (E) 
Experimental Study on the transport of microbeads with the lapse of time through 
perfusable blood vessel developed under 6.0 μl patterning volume condition. Scale bar = 
500 μm. (F) Confocal images exhibiting vasculogenesis formed from GFP-expressing 
HUVECs reflecting the effect of LFs spheroids. Observation of cytoskeleton through F-
actin (red) antibody staining. Scale bar = 1000 μm. 
 
Developmental studies and pathological studies on angiogenesis are very important studies. 
Various researchers are presenting a well-developed platform for angiogenesis in diverse 
styles. Nevertheless, the existing angiogenesis experimental model is not easy to use as a 
screening platform due to complicated device preparation and incompatibility with 
screening systems [109]. Our platform is feasible for use in various fields because it is 
convenient for the experimenter, from the preparation stage to the subsequent analysis. We 
obtained image results for all units in the device by performing one-time sample imaging 
with a microscope array setup for quantitative analysis. We considered the major factors 
and configurations of the cell conditions within a device. The modeling of the 
microvascular system through a fluid guide structure not only makes it easier to place cells, 
but also acts as a barrier to control the external and internal physicochemical stimulation. 
The main structural feature shows the hole provides a wider vertical space than the 
periphery, and this space can arrange the slope of the VEGF by additional sources. In other 
words, this space is effective in promoting angiogenesis once a tumor spheroid is captured. 
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These key findings are expected to reveal that the tumor spheroid-induced angiogenesis 
model can be implemented in an appropriate condition. 
3.3.4 Tumor migration and invasion 
Aggressive cancer cells are distinguished by increased cell migration and invasion. To 
investigate the role of TGF-β1 and TNF-α in cancer metastasis, the effects of TGF-β1 (20 
ng mL−1) and TNF-α (20 ng mL−1) were evaluated using Sphero-IMPACT. The U87MG 
tumor spheroid was located in the center of Sphero-IMPACT and embedded into 3D fibrin 
ECM, enabling reproducible and quantitative analysis of tumor spheroid migration and 
invasion. As shown in Figure 3.8, the invasion area after 48 h. was significantly increased 
in both the TGF-β1 and TNF-α treated group compared to the control group. These results 
demonstrate that both TGF-β1 and TNF-α significantly enhance the migratory and invasive 
potential of U87MG cancer cells. Furthermore, there was a statistically significant 
difference between the U87MG migration distance of the TGF-β1-treated group and that 
of the control group, but not between the TNF-α-treated group and the control. This 
suggests that TGF-β1 may promote morphological changes in U87MG. Increased 
malignancy is frequently related to an epithelial–mesenchymal transition, resulting in 
enhanced motility and the generation of cancer stem-like cells. Tumor cell migration 
normally occurs in response to hypoxia and soluble mediators (e.g., cytokines) [110]. 
Previous studies demonstrated that, in glioma, TGF-β1 is secreted from glioma cells via 
autocrine signaling, or is released from microglial cells. TGF-β1 expression has been 
reported to promote tumor cell survival, migration and invasion[111]. TNF-α can activate 
the mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) 
signaling pathway, upregulate matrix metalloproteinase (MMP)-9, and enhance tumor cell 
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invasion and metastasis [111]. Our findings are consistent with cancer cells becoming more 
aggressive when treated with TGF-β1 and TNF-α in the Sphero-IMPACT. Methods to 
investigate cell migration and invasion are important in cancer biology, immunology and 
cell biology. Conventional migration and invasion evaluation methods include cell culture 
wound closure assays, where a scratch is produced on a confluent cell monolayer, and 
Transwell cell migration and invasion assays, which are used to evaluate cell motility and 
invasiveness towards a chemo-attractant gradient [112]. However, these assays inherently 
lack 3D microenvironments with ECM and the ability to achieve reproducible, quantitative 
results. To address this issue, we developed a simple, reproducible single step tumor 
spheroid monitoring chip. We mixed tumor spheroids with ECM and loaded the tumor 
spheroid – gel suspension into the central channel. Our method can significantly accelerate 
and simplify the assay with a physiologically relevant 3D microenvironment, but at the 
same time produces highly reproducible results with 96-well plate format standardization. 
The assay can easily be modified with different types of matrices (e.g., collagen and 
Matrigel). Taken together, the Sphero-IMPACT can be applied to fully automated imaging 
and analysis of tumor cell migration with HTS and bridge the gap between 2D migration 
assays and in vivo studies. 
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Figure 3.8 Tumor invasion assay using a spheroid model. (A) Schematic depiction of 
tumor migration and invasion. (B) Configuration of the microfluidic device for modeling 
tumor spheroid migration and invasion into 3D ECM. (C) The optical microscope image 
showing the U87MG tumor spheroid in the spheroid region. Scale bar = 400 μm. (D) 
Representative confocal images of tumor migration and invasion under three different 
conditions. Scale bar = 600 μm. (E and F) Quantitative analysis of tumor cell migration 
area and migration distance. Bars indicate mean ± SEM from at least 4 devices per 
condition. *p < 0.1 and **p < 0.01 in the unpaired two-tailed Student's t-test. 
3.3.5 Tumor angiogenesis and drug screening 
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Angiogenesis is a key feature of tumor progression. The formation of new blood vessels 
from existing vessels can be induced by a number of tumor-derived soluble factors, such 
as the VEGF family[113]. Therefore, targeting these growth factors and their receptors has 
been used to treat several human cancers, including non-small cell lung cancer, 
glioblastoma, and renal cancers. We therefore investigated the effect of representative anti-
angiogenic cancer drugs, bevacizumab and sunitinib, in the Sphero-IMPACT. Before we 
investigated the effect of these anti-angiogenic drugs in the Sphero-IMPACT, we observed 
that within 4 days of co-culture, HUVECs invaded the fibrin matrix, apparently in response 
to U87MG-derived factors (Figure 3.9). Compared to the LF mediated vascular sprouting 
experiment, U87MG tumor spheroid mediated sprouting exhibited aberrant morphology 
(Figure 3.10). The addition of 1 mg mL−1 of bevacizumab and 1.0 μM of sunitinib 
significantly decreased the vascular network area, number of sprouts, and sprouting length, 
demonstrating their anti-angiogenic effects. We also tested the effect of cetuximab, which 
is an epidermal growth factor receptor (EGFR) inhibitor. In our model, there were no 
statistical differences between the cetuximab (1.0 mg mL−1)-treated group and the control 
group, in terms of vascular network area, number of sprouts, and sprouting length (Figure 
3.9D-F).  
As new cancer drugs are introduced for cancer treatment, and an increasing number of 
candidates progress through preclinical and clinical development, it is important to 
improve our understanding of the effects of cancer drugs on tumor blood vessels and tissues. 
Traditional well plate-based drug assays are still widely used in industry, thanks to their 
standardized format that enables automated handling. The Sphero-IMPACT not only 
provides a patho-physiologically relevant 3D TME compared to traditional well plate 
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assays, but also has a standardized 96-well plate format with robust and reproducible 
patterning capabilities. Indeed, PDMS has been widely accepted for fabricating 
microfluidics devices in prototyping experiments. However, due to several material 
limitations, PDMS is somewhat inaccessible, and it is difficult to scale up production of 
microfluidic cell cultures using this method. Therefore, we suggested using an injection-
molded device to replace existing PDMS microfluidics devices. The Sphero-IMPACT has 
the potential to provide a robust and reproducible high-throughput tumor spheroid 
experimental platform for vascularized TMEs. 
3.4 Conclusion 
Here, we presented an in vitro cell culture array platform “Sphero-IMPACT” that can be 
applied to large quantities drug screening for tumor angiogenesis. Our platform has several 
advantages, including compatibility with a range of laboratory equipment, ease of 
experimentation, and ready-to-use devices. We demonstrated the potential for this platform 
can be used as diverse assays in various fields such as biological laboratories and 
pharmaceutical companies. Through 3D printed prototypes, we performed optimized 
structural designs for 3D fluid patterning techniques and cell culture microenvironment. 
The final prototyped model was mass produced by injection molding. This process 
improves major problems with preexisting PDMS-based devices; low productivity, 
technical hurdles, and the validity of the results of experiments due to small molecule 
absorption. We developed Sphero-IMPACT that allows simultaneous patterning of a 
spheroid and cell-embedded hydrogels through a single-step patterning by open 
microfluidics. We established a variety of models on Sphero-IMPACT; (1) 3D perfusable 
blood vessel network, (2) tumor spheroid-based migration and invasion assay, and (3) 
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tumor spheroid-mediated angiogenesis model for drug screening. These in vitro models 
were reconstructed and validated under optimized conditions. Our previous research has 
included PDMS-based studies, these approaches have many limitations with respect to 
meeting the ultimate goals of cancer research. We aimed to develop a practical platform 
by focusing on improving the material properties of the device and experimental methods. 
Furthermore, we expect Sphero-IMPACT to be an experimental tool that end-user can 





Figure 3.9 Tumor spheroid-induced angiogenesis and drug screening validation (A) 
Schematic depiction of angiogenic sprouts toward tumor spheroid positioned in the center 
hole. (B) Configuration of the microfluidic platform for modeling tumor angiogenesis. The 
tumor spheroid collected and mixed with fibrin gel is injected into the hole, and HUVECs 
are seeded on around the fibrin gel surface. (C) Maximum projection images of the tumor 
angiogenesis cultured for 4 days in Sphero-IMPACT. Tumor spheroid formed from GFP-
expressing U87MG, and blood vessels assembled from RFP-expressing HUVECs. Under 
the same culture conditions, the types of target drugs were treated with medium every two 
days. Scale bar = 500 μm. (D–F) Quantitative analysis of the total vascular network area, 
number of sprouts and sprouting length depending on each drug condition. Bars represent 
mean ± SEM from at least 8 devices per condition. ****p < 0.0001 in the unpaired two-
tailed Student's t-test. 
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Figure 3.10 Comparison of angiogenic sprouts under different conditions. Under co-
culture with U87MG cancer cells, angiogenic sprouts are characterized by the sprouts 
with branching tip cells (red arrow) and convoluted and aberrantly converged blood 







CHAPTER 4. GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES 
To reconstitute a physiologically relevant tumor microenvironment on a chip, several key 
parameters need to be taken into account. In this section, we will discuss unique 
characteristics of an in vivo TME to consider improvements to in vitro TME microfluidic 
models for drug delivery studies. 
4.1 EPR Effect 
The preferential accumulation of nanoparticles in a tumor is generally attributed to 
defective and leaky tumor vasculature [114] and dysfunctional lymphatic vessels in the 
tissue that cause poor drainage [115]. All of these factors are mainly known to contribute 
to the EPR effect, facilitating nanoparticle delivery to a solid tumor site [116]. 
Conventional in vitro 2D models however were unable to evaluate the full extent of the 
EPR effect. 
4.2 Solid Tumor Stress 
It has long been known that tissue stiffness is higher than normal in fibrotic solid tumors 
[117]. Tumors containing abnormally high amounts of collagen and other scaffolding 
proteins have been linked to several hallmark characteristics of cancer, including tumor 
growth, invasiveness, and metastasis [118]. Accumulation of mechanical stresses within 
the TME may lead to the constriction of intratumoral blood vessels, drastically reducing 
oxygen supply and increasing the risk of hypoxia and necrosis [119]. Moreover, vessel 
compression decreases blood flow, which also reduces the delivery efficacy of drugs to 
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ultimately compromise therapeutic outcomes [120]. Apart from compression of 
intratumoral vessels, the solid stress directly affects cancer cells by increasing their 
apoptotic rate and reducing proliferation [121]. With the widely-known contribution of 
mechanical stress to tumor progression, biomechanical models of tumor growth have been 
developed to consider the generation and accumulation of mechanical stresses in tumors 
[122]. However, few microfluidic model-based studies focused on the incorporation of 
solid tumor stress, which is key to the design of physiologically relevant in vitro tumor 
models. 
4.3 Normalization of Tumor Blood Vessels 
The physiological consequences of tumor vascular abnormalities include temporal and 
spatial heterogeneity in tumor blood flow and increased fluid pressure [123]. These 
abnormalities promote tumor progression and lead to reduction in the distribution of an 
anti-cancer drug. Therefore, one of the main purposes to include vascular normalization 
into microfluidic platforms is to examine the phenotypic transformation of abnormal 
vasculature into a phenotype that closely resembles functionally normal blood vessels by 
increasing coverage of pericytes and the basement membrane, eventually decreasing vessel 
permeability [124]. Tumor vascular normalization repairs not only abnormal morphology 
but also the function of tumor vasculature, by correcting angiogenic signaling pathways 
[125]. However, normalized vessels with reduced fenestration may also hinder EPR-effect 
based delivery of large nanoparticles to the tumor site. Therefore, exploring the appropriate 
tumor vessel normalization may be needed to improve and balance nanomedicine delivery 
to a tumor site [126]. Previous models to investigate dynamic changes during tumor 
vasculature normalization heavily rely on computational models and mouse models [127]. 
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Microfluidic platforms may provide a better understanding of the molecular, cellular, and 
functional changes during dynamic tumor vessel normalization with physiological 
relevance. 
4.4 Future Microfluidic Platforms 
Many of the microfluidic platforms are based on soft lithographic PDMS designs that were 
developed and fabricated in-house or procured from limited fabrication runs from an 
associated institution. Initially developed as a means of rapid prototyping, soft lithography 
is ideal for microfabrication at the pilot scale, with low per-design initial investment for 
producing a limited run. Although soft lithography enables the production of a novel 
functional microfluidic design in PDMS within 24 h of drafting, the method utilizes fragile 
silicon wafer molds and heavily bottlenecked PDMS casting steps which limits the 
scalability of higher throughput fabrication. To address the larger scale production 
inefficiencies inherent to soft lithographic microfabrication, many commercial and 
academic ventures such as Emulate, MIMETAS, and Curiochips have looked to 
comparatively more upscalable manufacturing techniques such as injection molding and 
3D printing for microfluidic device production. Incorporating large scale manufacturing 
practices into microfluidic chip production is a significant step towards ensuring that 
industrial scale demands can be supplied. 
Development efforts to scale up production capabilities have also enabled a greater degree 
of quality control and form factor standardization for high throughput compatibility. Many 
conventionally produced PDMS microfluidic devices are punched manually or punched in 
a device-specific configuration, producing distinct form factors and input/output ports 
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which may vary significantly even within devices of the same design. The implementation 
of standardized, mass production friendly templates produced in large, uniform batches 
enables the possibility of automated handling through existing microtiter plate HTS 
infrastructure. 
While the forefront of academic microfluidic tissue platform research continues to 
specialize towards increasingly sophisticated designs for higher fidelity in vivo like 
reconstitution, development for industrial applications have focused on simplifying designs 
in favor of flexible platforms that are simultaneously easier to use and are capable of 
applying to a wider range of tissues. Although the strategy of simplification sacrifices 
aspects of realistic tissue generation, a balance between lesser but still meaningful levels 
of realism and greater accessibility for a wider user base may prove instrumental for 
industrial scale adoption. Although organ-on-a-chip technology is still in its infancy, it will 
surely continue to expand to provide physiologically/pathologically relevant tumor 








CHAPTER 5. CONCLUSION 
This thesis described two different approaches to reconstitute 3D vascularized tumor 
microenvironment using PDMS and injection-molded -based microengineered fabrication 
technology. We designed geometrically defined vascularized tumor spheroid model and 
investigated hallmarks of tumor vasculatures and highlighted significance of tumor 
vascularization and revealing the importance of treatment timing. Based on the model, we 
further developed injection-molded plastic array 3D spheroid culture platform, which made 
of polystyrene (PS) in a standardized 96-well plate format with user-friendly interface. The 
platform that mediate open microfluidics allows implement spontaneous fluid patterning 
with high repeatability from the end user. To demonstrate versatile use of the platform, we 
developed 3D perfusable blood vessel network and tumor spheroid assays. In addition, we 
established a tumor spheroid induced angiogenesis model that can be applicable for drug 
screening.  
To build these in vitro TME model systems is essential to acquire a deeper understanding 
of the cellular and molecular mechanisms by which the TME contributes to tumor growth 
and metastasis. Traditional 2D in vitro systems, Transwell culture, and spheroid formation 
models that are used to mimic TME have shown limited effectiveness in predicting the 
efficacy of many candidate drug compounds. Vascularized tumor spheroid model that 
introduced in this thesis may enable us to study tumor microenvironment in real-time in a 
precisely controlled manner. Our vascularized model can address the key challenges of 
conventional platforms and enable more complex yet critical studies with multi-parametric 
interactions including cell-to-cell and cell-to-matrix interactions within the TME.  
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In this thesis, we incorporated tumor-like spheroids into a microfluidic chip showed the 
penetration of nanoparticles into a tumor tissue with physiological flow conditions, 
validating the EPR effect in vitro. Likewise, the next generation of microfluidic devices 
would possibly use patient derived cells and extracted non-cellular ECMs with the use of 
multiple biochemical, biophysical and biomechanical cues that are characterized in cancer 
(EPR effect, solid tumor stress, and blood vessel normalization). This approach will also 
be integrated with high detection efficiency and high throughput technologies to enhance 
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